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PREFACE 
This dissertation is presented in an article format. The findings of the study are presented in 
chapter 3 and chapter 4, in manuscript format, as required by the regulations of the University 
of KwaZulu-Natal. The manuscript in chapter 3 has been submitted for publication to the 
Journal of Pharmacy Practice. The systematic review manuscript in chapter 4 will be submitted 
for publication to BMC Public Health. The references used in the manuscripts were cited 
according to the instructions/guidelines for authors as required by the journals.  
The dissertation consists of five chapters as follows:  
Chapter 1: Introduction highlights the background, problem statement and rationale of the 
study. It further describes the research questions, the aim and objectives of the study, a brief 
methodology and overview of the dissertation. 
Chapter 2: Highlights the literature background to the study by providing an overview of 
adverse drug reactions, pharmacovigilance, ADR monitoring, post-marketing surveillance, and 
the efficacy and safety of vilazodone.  
Chapter 3: Manuscript titled “The safety profile of vilazodone - a study on post-marketing 
surveillance” written according to the author guidelines and submitted for publication to the 
Journal of Pharmacy Practice. 
Chapter 4: Manuscript titled “A systematic review based on the psychiatric adverse effects 
associated with the use of vilazodone” written according to the author guidelines to be 
submitted for publication to BMC Public Health. 
Chapter 5: Provides the synthesis which includes general conclusions, significant findings, 
strengths and limitations of the study and recommendations are provided. 
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ABSTRACT 
Background and Aim 
Vilazodone was approved in 2011 as an antidepressant to treat major depressive disorder. Like 
other antidepressants, vilazodone has adverse effects associated with the use of the drug. Being 
a relatively new drug, it is not clear if all adverse effects have been identified yet. The aim of 
this study was therefore to review the adverse effects reported to the WHO Programme for 
International Drug Monitoring (PIDM). This study then went on to explore the psychiatric 
adverse effects associated with the use of vilazodone and the factors that have been 
hypothesized as being responsible for these effects. This study aims to provide a critical 
summation of present findings to add to the knowledge about the safety profile and adverse 
effects caused by vilazodone. 
Method  
Data on adverse effects reported for vilazodone was obtained from the database VigiAccess 
managed by PIDM. Data was extracted from VigiAccess using Excel® and analysed using 
descriptive statistics. The data collected was compared to the patient information leaflet (PIL) 
of Viibryd® and the FDA documents to determine adverse drug reactions reported post 
marketing. In order to further explore the psychiatric adverse effects associated with 
vilazodone, a systematic review was conducted. Databases and reference lists for studies 
published between January 2000 to January 2020 were searched and a systematic review was 
conducted using the Cochrane Framework.  Primary studies were screened for inclusion and a 
critical appraisal performed. Data was analysed and frequency tables were used to summarise 
the data followed by a narrative synthesis. 
Results 
A total of 9708 adverse events had been recorded on VigiAccess of which 6054 were not 
recorded on the PIL and the FDA approval document. Most of the reports were received from 
the Americas and were for adult women aged 45-64 years (24%, n=1059). The highest number 
of adverse events reported were for psychiatric events (19%; n=1889), followed by gastro-
intestinal effects (18%; n=1839). Specific psychiatric disorders recorded included anxiety 
(316), depression (208), hallucination (168) and agitation (142). The systematic review 
confirmed several psychiatric adverse effects associated with the use of vilazodone. The 
findings of this study suggested that these common psychiatric adverse effects associated with 
xvi 
 
the use of vilazodone were not known during the time of FDA approval of the drug and is not 
currently recorded in the patient information leaflet (PIL). 
Conclusions 
In summary, this study found several adverse drug reactions not recorded in documents 
emanating from clinical trials pre-marketing. This highlights the importance of continued post-
marketing surveillance of a drug, as well as the need for further studies on the psychiatric 
adverse events associated with vilazodone in order to improve the safety profile. 
Keywords: Vilazodone, antidepressant, SSRI, major depressive disorder, pharmacovigilance, 
adverse drug reactions, post-marketing surveillance 
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CHAPTER 1 
INTRODUCTION 
This chapter provides the background of the study, problem statement and rationale of the 
study. It includes the research questions, aim and objectives and significance of the study. A 
general overview of the methodology has been included. 
Background 
Pharmacovigilance is defined as “the science and activities relating to the  detection, 
assessment, understanding and prevention of adverse effects or any other drug-related 
problem” (World Health Organisation, 2004). It involves monitoring the effects of medicines 
after they have been approved for use to identify any previously unknown or unreported 
adverse drug reactions (ADRs). Before new medicines are registered, clinical trials are 
conducted to verify their efficacy and safety. Since the sample sizes used in clinical trials are 
much smaller than the populations that use the medicines, certain ADRs are only identified 
after the medicine has already been licensed for use (Selker et al., 2018) The purpose of 
pharmacovigilance is to detect, characterise, and mitigate these ADRs.  
Post-marketing surveillance (PMS) is the process of identification, collection of information 
and practice of monitoring the safety of a pharmaceutical drug after it has been approved and 
released on to the market (Raj et al., 2019). This is an important part of  pharmacovigilance. 
PMS evaluates pharmaceutical drugs taken by individuals under a wide range of circumstances 
and over an extended period (Raj et al., 2019). 
Post-marketing pharmacovigilance is essential as adverse reactions to a drug often only 
becomes apparent after a drug enters clinical practice (Jeetu et al., 2010). Once marketed, the 
medicines are used by different patients’ populations who have various diseases and who use 
several other drugs which may affect how they will react to the drug (Jeetu et al., 2010) 
Therefore, the adverse drug reactions need to be monitored amongst different populations. 
PMS studies can also provide valuable information on the use of drugs in special patient 
populations such as pregnant women, paediatrics and geriatrics, which is not obtained from 
pre-marketing studies due to ethical reasons. PMS further allows for the monitoring of 
populations not studied in clinical trials, such as patients with multiple comorbidities that may 
react differently to a drug (Suvarna, 2010).  
2 
 
The process of PMS can, therefore, refine, confirm or deny the safety of a drug (Raj et al., 
2019). This process uses a number of approaches to monitor drug safety, including spontaneous 
reporting databases, prescription event monitoring, electronic health records and patient 
registries (Raj et al., 2019). The Food and Drug Administration (FDA) ensures the safety and 
efficacy of drugs available in the US (US Food and Drug Administration. 2011). In South 
Africa, the South African Health Products Regulatory Authority (SAHPRA), formerly known 
as the Medicines Control Council (MCC) are committed to improving drug safety through 
adverse drug reaction monitoring and reporting of adverse drug reactions.  
Adverse drug reactions are presented on Patient Information Leaflets (PIL), specifically for 
patients and prescribers. A patient information leaflet is a document included in every medicine 
package to offer written information about the medication (Herber et al., 2014). The 
manufacturer provides PIL to inform patients about their medicines regarding its 
administration, precautions, and potential side effects. 
Vilazodone is a drug used in the treatment of major depressive disorder (Hellerstein et al., 
2015). It is relatively new drug that was released on to the market in 2011 and there is currently 
no therapeutically equivalent version of Viibryd® available. The aim of this study was to review 
current knowledge on the safety profile of vilazodone, the psychiatric adverse effects 
associated with the use of vilazodone and the need for continuous post-marketing surveillance.  
1.1 Rationale for this study 
Major depressive disorder (MDD) is a severe chronic and recurrent psychiatric illness and 
accounts for 10%–14% of all patients seen by primary care physicians (Yu et al., 2015). MDD 
is one of the major causes of disability globally (Gohil et al., 2015).   The burden of the disease 
worldwide includes symptoms of decreased pleasure or interest in daily activities, changes in 
appetite or weight, sleep disorders, difficulty concentrating, fatigue, psychomotor agitation, 
sad mood, feelings of worthlessness, and even suicidal thoughts (Gohil et al., 2015). 
Despite the availability of different types of antidepressants, many patients with depression do 
not achieve adequate results (Al-Harbi, 2012). Selective serotonin (5-HT)-reuptake inhibitors 
(SSRIs) are prescribed as first-line treatment options, but many patients do not adequately 
respond to an SSRI (Al-Harbi, 2012). Although all SSRIs modulate serotonin reuptake, they 
differ in their pharmacological properties and thus efficacy and safety in individual patients. 
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Despite numerous antidepressants being available, more than 30% of patients do not achieve 
adequate relief (Penn et al., 2012).  
Vilazodone, sold under the brand name Viibryd®, is a medication used to treat MDD (Cruz, 
2012). There are currently numerous effective antidepressants on the market that have been 
available for much longer than vilazodone. However, vilazodone has an advantage because it 
offers a dissimilar mechanism that produces remission of depressive symptoms (Singh et al., 
2012). Thus, vilazodone provides a new alternative in the treatment of depressions. The unique 
mechanism of action of vilazodone lies in the fact that it simultaneously acts as an SSRI as 
well as a 5-HT1A-receptor partial agonist and thus is speculated to be effective and well-
tolerated for patients with MDD symptoms (Zhang et al., 2015). Vilazodone binds with high 
affinity to the serotonin reuptake site but not to the norepinephrine or dopamine reuptake site 
(Cruz, 2012). 
In previous studies and reports, it is reported that vilazodone is effective and safe, with a low 
occurrence of side effects. It offers promise as an effective oral drug with a balance of efficacy 
and tolerability (Zhang et al., 2015). Over the years, several other adverse effects including 
diarrhoea, headache, nausea, vomiting and insomnia have been identified (Wang et al., 2016).  
However, being a new drug, it is not clear if all adverse effects have been identified. The 
purpose of the present study was to therefore review the adverse effects associated with 
vilazodone.  
 
1.2 Aims and objectives for this study 
The aim of this study was to explore the adverse effects associated with the use of vilazodone. 
To achieve this, the following specific objectives were outlined:  
1.2.1 To quantify the adverse effects associated with vilazodone reported in VigiAccess, 
according to organ systems. 
1.2.2 To compare the adverse effects reported in VigiAccess to the adverse effects indicated 
during the FDA approval process. 
1.2.3 To compare the adverse effects reported in VigiAccess to adverse effects indicated on 
the PIL for Viibryd®. 
1.2.4 To further explore associated psychiatric adverse effects. 
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1.3 Significance of the study 
The study of the safety profile of any drug is a significant and relevant part of 
pharmacovigilance. Monitoring of the drug post-marketing is necessary as drugs are used 
amongst varied populations with several comorbidities and concomitant medication use. PMS 
provides valuable information on the use of medications in these special patient populations as 
well as allowing for the long-term monitoring of the effects of drugs.  
As a relatively new drug, it is important to monitor vilazodone’s adverse effects to improve 
and ensure the safety of the drug’s use by patients. Studying the safety profile of vilazodone 
will give a greater insight into the safe use of this medicine.   
1.4 Research methodology  
 
1.4.1 Study design 
In order to determine the occurrence of ADRs not recorded at the time of FDA registration, 
data was obtained from VigiAccess (World Health Organisation, 2015) and subsequently 
compared to ADRs in the FDA approval document 
(https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022567s000lbl.pdf) and PIL 
(https://media.allergan.com/actavis/actavis/media/allergan-pdf-documents/product-
prescribing/2018-05-8-Viibryd(vilazodone)-USPI-Clean.pdf). Further investigation on the 
psychiatric ADRs were done via a systematic review (to be discussed in chapter 4). 
 
1.4.2 Data source 
VigiAccess allows access to information on side effects reported to the World Health 
Organization (WHO) Program for International Drug Monitoring (PIDM). VigiAccess was 
launched on 17 April 2015. It is the WHO international database of adverse drug reactions and 
has over 10 million reports dating back to 1968. It holds information from more than 120 
countries participating in WHO PIDM. 
This database presents ADRs in terms of body system, and provides demographics including, 
age, gender, and location (per continent). Specific patient information is not provided in the 
database, thus underlying medical conditions, mediation, and specific patient demographics are 
not available. Using the data available on this database, it was possible to quantify the adverse 
effects per body system, associated with the use of vilazodone. 
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For the systematic review conducted, a literature search using multiple databases, including 
Pubmed (Medline), Proquest Psychology Journals, Web of Science, Taylor & Francis Online 
Journals, PsychInfo, and Wiley Online Library. Additional searches were performed in Google 
Scholar. Studies were limited to publication date from January 2000 to April 2020 as the patent 
of vilazodone for registration was only received in 2011.  
 
1.4.3 Data extraction 
Data was extracted from VigiAccess using Excel . Numeric data was extracted according to 
body system in the form of a table stating the number of previously unrecorded adverse drug 
incidents. Find below sample of data extraction sheet for blood and lymphatic system.: 
Table 1: Data extraction tool for blood and lymphatic system from VigiAccess. 
 
For the systematic review study, a predesigned data extraction form was employed and 
prepared in a Microsoft Excel® sheet. The following data were extracted: bibliographic 
information, study characteristics, participants’ characteristics, treatment information, 
description of psychiatric adverse effects and outcome of interest.  
 
1.4.4 Data analysis 
Once the data was extracted from the database VigiAccess, the data was analysed using Excel. 
Descriptive statistics was done, and data presented in the form of graphs and tables. The data 
collected was compared to adverse drug reactions of vilazodone listed on the PIL and FDA. 
For the systematic review study, data was imported into SPSS Software for analysis. Frequency 
tables summarized categorical data, including sample characteristics, patient characteristics 
and psychiatric adverse effect outcomes. Psychiatric adverse effects found from selected 
articles were listed according to preferred terms based on the most commonly used coding 
Blood and Lymphatic System  
Subgroup of Medical Conditions Number of Incidences Reported 
Anaemia  
 
Lymphadenopathy 
 
Blood Disorder 
 
Increased Tendency to bruise 
 
Splenic Vein Thrombosis 
 
Splenomegaly 
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system, the Medical Dictionary for Regulatory Activities (MedDRA). A narrative synthesis 
was then done to describe and discuss the outcomes.  
 
1.4.5 Data Management 
The data extraction sheet was stored on a password protected computer and backed up on 
Google Drive®. Data will be removed upon completed dissemination of results. The 
bibliographic software (Endnote), was used for the data management of retrieved references. 
All the results of the literature searches were imported into the Endnote program and duplicates 
were removed. 
 
1.5.Ethical approval  
The data accessed in this study is in the public domain readily accessible on the internet and 
does not contain any personal information that can be linked to real people. A waiver of ethical 
approval was obtained from the School of Health Sciences, University of Kwa-Zulu-Natal 
(Annexure 1). 
 
1.6 Chapter summary   
This chapter provided background and rationale to the study, explaining pharmacovigilance, 
its importance, post-marketing surveillance, FDA approval, and the reasons why reporting of 
ADRs is important. The chapter gives a short overview of vilazodone. It also defines the aims, 
objectives, and a brief overview of the methodology.  
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Introduction   
This chapter provides a literature background to the study. The context of this literature review 
is set by first providing an overview of adverse drug reactions, pharmacovigilance, adverse 
drug reaction monitoring, pre-marketing clinical trials and post marketing ADR surveillance, 
approaches to improving pharmacovigilance, the safety profile of vilazodone and concludes 
with studies conducted to evaluate the safety and efficacy of vilazodone for the management 
of depression and anxiety disorders.  
2.2 Adverse drug reactions (ADRs) 
Over the years, drugs have changed how diseases are treated.  However, the use of medicine 
has the possibility of unintended consequences. When harmful, these effects are referred to as 
adverse drug reactions (ADRs) (Vural et al., 2015). An ADR is defined as “any response to a 
drug which is noxious and unintended that occurs at doses normally used in man for 
prophylaxis, diagnosis, therapy of disease, or for the modification of physiologic function” 
(World Health Organization, 2004). 
Adverse drug reactions (ADRs) can affect patients irrespective of age, gender, location or 
occupation, ultimately impacting on morbidity and mortality (Bogolubova et al., 2018). ADRs 
have become a major global health problem that needs to be addressed (Coleman et al, 2016). 
According to a study ADRs can be the 4th – 6th prime cause of death in the United States with 
the contribution of more than 100 000 deaths annually (Pirmohamed et al., 2004). In South 
Africa, it was estimated that 6.3% of hospitalised patients were admitted due to an ADR (Mehta 
et al., 2017). 
Adverse drug reactions are categorised into events that occur seldomly and occur at an 
increased rate in the general population (Inácio et al., 2017). ADRs are further subdivided into 
categories according to the drugs’ use: ADRs that occur with short-term use, ADRs that occur 
with long-term use, and those that occur after discontinuation of the drug (Coleman et al., 
2016). Knowledge of the most common ADRs and population groups that are prone to 
experiencing ADRs will allow the National Department of Health (NDoH) to strengthen 
strategies to maximize patient safety and ensure the rational use of medicines (Jimmy et al., 
2011). 
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2.3 Pharmacovigilance 
Pharmacovigilance (PV) is defined as the “science and activities relating to the detection, 
assessment, understanding, and prevention of adverse effects or any other drug-related 
problem” (World Health Organization, 2004). Pharmacovigilance describes the processes for 
monitoring, evaluating and detecting ADRs that were previously unknown and is the main 
component for ensuring effective drug regulation systems (Jeetu et al., 2010).  
In order to improve public health, pharmacovigilance mechanisms to evaluate and monitor the 
safety of medicines are necessary. Pharmacovigilance plays a vital role in ensuring that doctors 
and patients have enough information to decide on a drug of choice for treatment as well as the 
dangers and benefits involved with a drug (Jeetu et al., 2010).  
When a new drug is released into the market, there is still some unknown information about 
its’ safety (Berlin et al., 2008). Unexpected adverse events could arise at any time in the life 
cycle of a drug and could put the user at risk. During the pre-marketing phase, information 
regarding possible ADRs are incomplete as special groups such as children, pregnant women 
and the elderly are excluded from clinical trials (World Health Organization, 2012). Patients 
that are studied in the pre-marketing clinical trials of new medicines are usually limited to a 
small number and are studied for a short period (Duijnhoven et al., 2013). Therefore, 
pharmacovigilance initiatives after pre-marketing trials are required through post marketing 
surveillance to ensure the safety and efficacy of medicines throughout its’ use. 
Pharmacovigilance initiatives in South Africa are determined by three groups, the 
pharmaceutical industry, health care professionals, and public health programmes (Mehta et 
al., 2017). Adverse drug reaction reporting through these three initiatives aims at using ADR 
reports as a tool in clinical practice to increase the generation of ADR signals (Mehta et al., 
2017). The WHO defines a signal as “Reported information on a possible causal relationship 
between an adverse event and a drug, of which the relationship is unknown or incompletely 
documented previously” (World Health Organisation, 2012). The process of detecting and 
assessing signals forms the most important aspect of pharmacovigilance. These signals can be 
generated by using sources such as spontaneous reporting, case control studies, cohort studies, 
pre-clinical and clinical trials (Talbot et al., 1998).  
After a signal has been detected, reporting and analysis are carried out by a medical practitioner 
and sent to regional pharmacovigilance centres to be monitored (Inácio et al., 2017). After 
monitoring, laboratory tests and adherence counselling, the ADR report form is filled and 
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submitted to the National Department of Health to be filed in database records. This form 
indicates the patients’ data, the ADR, current treatment and concomitant diseases (Mehta et al., 
2017). 
Spontaneous reporting is the most common method for ADR reporting used in 
pharmacovigilance practiced worldwide as part of the WHO Programme for International Drug 
Monitoring system (Nadew et al., 2020). The purpose of spontaneous reporting is the early 
detection of new and harmful ADRs signals during the process of diagnosis and treatment. 
Detecting unknown safety signals quickly from post-marketing data through spontaneous 
reporting is one of the main challenges of pharmacovigilance (Kumar et al., 2015). According 
to a study, it was observed that over 94% of all ADRs through spontaneous reporting are 
unreported (Kumar et al., 2015).  
Health care professionals play a significant part in pharmacovigilance systems and are 
encouraged and obligated to report ADRs. The quantity of data collated and reported, is 
dependent on the level of awareness and determination of the health care professional 
(Bogolubova et al., 2018). Therefore, pharmacovigilance is required throughout the patient-
practitioner relationship, when patients are being asked about their drug use and history and 
when diagnosing, prescribing, monitoring, and reassessing management of a condition (Mehta 
et al., 2017). In order to ensure safe medicine use, follow-ups are essential to the discovery of 
ADRs and are vital for as long as a medicine remains on the market. Failing to maintain 
consistent pharmacovigilance when using drugs in patients can have fatal consequences (Mehta 
et al., 2017). 
2.4 ADR Monitoring 
The early identification of patients at risk for ADRs can help health care professionals make 
better decisions regarding drug monitoring and management. Early detection or prevention of 
ADRs can help decrease the unnecessary cost burden associated with these effects (Sahu et al., 
2014).  
Underreporting of ADRs by medical professionals remains a global issue (Güner et al., 2019). 
When a patient experiences an ADR, the health care professional prescribing the drug is usually 
involved in treating the ADR and has the clinical expertise to estimate the probability that a 
drug has caused an ADR in the patient (Coleman et al., 2016). Unfortunately, health care 
professionals infrequently report suspected ADRs and it is commonly estimated that that only 
1% to 10% of significant ADRs are reported (Klein et al., 2013).   
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The continued surveillance by health care professionals will enable the quick detection of any 
emerging signals, increase the reporting and awareness of ADRs and, reduce the ADR 
incidence rate (Shamim et al., 2016). Therefore, proper implementation of continued ADR 
monitoring will reduce detrimental effects and improve the rational use and selection of drugs 
(Coleman et al., 2016) 
Pre-clinical or pre-marketing trials refer to the first step conducted in safety studies to 
determine a drugs’ safety. This process involves in-vitro and in-vivo testing to determine the 
efficacy, toxicity and pharmacokinetic profiles of a drug (Andrade et al., 2016). Clinical trials 
involve multiple steps including laboratory investigations, clinical examination of patients and 
ADR monitoring.                                                                     
Phase 0, also known as the first step of human trials is aimed at early decision making and 
includes giving subtherapeutic doses of a drug to a few volunteers (Karakunnel et al., 2018). 
Phase I is conducted to access and approve the tolerability and safety of a drug to be used in 
humans. This process usually takes 6-9 months and involves approximately 20 to 100 healthy 
volunteers who are given single doses of the drug (Karakunnel et al., 2018).  
Phase II is used to assess the therapeutic activity and tolerance of a drug for long-term use to 
determine the most suitable dose to be used in humans. This process takes approximately six 
months to three years and can be conducted either as case series or randomized controlled trials 
involving a drug compared to a placebo. The drug is tested using 100- 500 patients to determine 
its’ safety and effectiveness (Karakunnel et al., 2018). 
Phase III involves determining the efficacy of a drug and includes larger groups of volunteer 
patients (1,000-5,000). Double blind randomized controlled trials are conducted to create 
substantial safety and efficacy data of a drug based on its risk and benefit relationship 
(Karakunnel et al., 2018). This phase determines the actual response of a drug and hence is a 
costly and time-consuming process that usually lasts approximately 1-4 years. As soon as the 
drug is deemed effective and safe for human use, data is compiled and sent for marketing 
approval to regulatory authorities (Karakunnel et al., 2018). 
Post-marketing surveillance (PMS), also known as Phase IV of clinical trials, refers to the 
process of monitoring the safety of drugs after completion of clinical trials (Raj et al., 2019). 
The aim of ADR monitoring through post-marketing surveillance is to prevent untoward effects 
that could diminish a patient’s quality of life, lead to death and have a negative impact on 
patient adherence (Raj et al., 2019). The prompt reporting of any adverse reaction to a drug can 
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lead to the early detection of unknown side effects and reactions (Klein et al., 2013). Post-
marketing surveillance is important as it is the only means of obtaining information on the 
mutagenic and teratogenic effects of drugs in humans and allows for the long-term monitoring 
of the effects of drugs (Raj et al., 2019). The post-market surveillance for adverse events begins 
once the drug becomes available to the public and continues for as long as it is available on the 
market (Suvarna, 2010).  
2.5 Vilazodone 
In this study, vilazodone was used as a study example, as it is a relatively new drug used in the 
management of MDD. MDD is a severe, chronic and recurring mental disability, and the third 
leading cause of severe burden of disease in the world (World Health Organisation, 2012). The 
symptoms of MDD include changes in appetite and weight, sleeping difficulties, difficulties in 
concentration, fatigue, and suicidal thoughts (Kennedy, 2008). Despite the availability of 
several antidepressants, there are still over 30% of patients with MDD who do not achieve a 
satisfactory response (Al-Harbi, 2012). Some of the most significant issues affecting treatment 
discontinuation and non-adherence to antidepressants are limited efficacy, delayed onset of the 
drug, and the incidences of intolerable ADRs (Srimongkon et al., 2018).  
In 2011, the US Food and Drug Administration (FDA) approved the use of vilazodone for the 
treatment of MDD in adults (Zhang et al., 2015). FDA approval of a drug means that data 
collected from clinical trials and testing on the drugs’ effects have been reviewed with benefits 
that outweigh the potential risks of the drug (US Food and Drug Administration, 2019).  
Vilazodone is a novel antidepressant with a unique mechanism of action by simultaneously 
acting as a selective serotonin reuptake inhibitor (SSRI) and a 5-HT1A-receptor partial agonist 
(Zhang et al, 2015). Wang et al. speculated that vilazodone has three benefits compared to other 
antidepressants, owing to its combined serotonin reuptake inhibition and anxiolytic mechanism 
(Wang et al., 2016). These benefits of vilazodone include a faster onset of action, better 
efficacy, and improved tolerability (Wang et al., 2016). Vilazodone acts as a partial agonist at 
serotonin receptors, which results in faster desensitization of 5-HT1A auto receptors without an 
excess activation of serotonin inhibition. Vilazodone binds to the serotonin reuptake site with 
a higher affinity for an extended period, which contributes to greater desensitization leading to 
a faster onset of action than conventional selective serotonin reuptake inhibitors (SSRIs) (Wang 
et al., 2016).  
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Vilazodone presents with various adverse effects significantly; diarrhoea, headache, nausea, 
vomiting, dizziness, and insomnia, which have been identified during the pre-marketing phase 
of the drug (Wang et al., 2016). As with long term exposure to other antidepressants, 
vilazodone is also associated with increased obesity (Carvalho et al., 2016). Vilazodone acts 
on the CNS and increases the risk of suicidal thoughts and behaviour in children and adults 
(Hellerstein et al., 2015), as is common is some other antidepressant drugs. Also, of note is the 
lower risk of sexual adverse effects possibly caused by the 5-HT1A post-synaptic receptor 
actions (Wang et al., 2016). 
2.5.1 Safety and efficacy studies of vilazodone  
Several post-marketing studies have been conducted to elaborate on the safety and efficacy of 
vilazodone. A large, double-blind, randomised, placebo-controlled trial to test the effectiveness 
of the drug for the management of MDD in comparison to a placebo used found a significant 
improvement in depression scores associated with the use of vilazodone (Rickels et al., 2009) 
Patients in the age category of between 18-70 years old diagnosed with MDD were given 
40mg/day of vilazodone or placebo once daily with food over  two weeks.  Four hundred thirty-
six patients were given vilazodone, and 433 patients received the placebo drug for which the 
results received were compared after eight weeks (Rickels et al., 2009).  In this study, 
vilazodone showed a significant advancement in the transformation from baseline to week 8 in 
the Montgomery-Asberg Depression Rating Scale (MADRS) and on the 17-item Hamilton 
Depression Rating Scale (HDRS-17) total scores in comparison to the placebo drug used. 
Differences between the use of vilazodone and the placebo on the MADRS and HAM-D-17 
scales were seen after only one week of treatment (Rickels et al., 2009). 
The adverse effects recorded in this study had an incident rate of more than 5% in patients who 
were treated with vilazodone (Rickels et al., 2009). 28% of patients experienced diarrhoea, 
dizziness occurred in 8.5% of patients, insomnia occurred in 6% of patients and 4.6% of 
patients experienced vomiting (Rickels et al., 2009). Further adverse effects included decreased 
libido, dry mouth, arthralgia, fatigue palpitations and abnormal dreams. 
According to an open-label, multicentre study, it was shown that vilazodone given at 40 mg/day 
was well tolerated for the short- and long-term management of MDD (Wang et al., 2016).In a 
phase 3 randomised controlled trial by Khan et al. vilazodone at 40mg/day showed 
improvements in symptoms of depression on multiple measures of depression scales during  
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eight weeks of treatment. The use of vilazodone was also seen to show improvements in illness 
severity (Khan et al., 2011). 
In a phase 4 randomised controlled trial over ten weeks, a 20 mg/day dose of vilazodone, a 40 
mg/day dose vilazodone, a 40 mg/day dose of citalopram, and a placebo were compared 
(Mathews et al., 2015). The depression scale MADRS and symptom severity improvement 
scores were greater for vilazodone 20 mg/day compared to the other drugs used. The adverse 
drug reactions caused included diarrhoea, nausea, vomiting, and insomnia and occurred in more 
than 5% of the vilazodone group and 0.7% in the placebo group (Mathews et al., 2015). The 
majority of ADRs that occurred were mild or moderate in severity. Serious ADRs were 
reported in four patients treated with vilazodone and six patients treated with citalopram.  
A phase 4 double-blind randomised placebo-controlled study was undertaken over  eight weeks 
in which 253 patients were given vilazodone at 40mg/day, and 252 patients were given a 
placebo (Croft et al., 2013). The MADRS depression improvement score was much higher for 
vilazodone than the placebo. ADRs reported were diarrhoea, nausea, dizziness, and insomnia. 
Gastrointestinal effects such as nausea and diarrhoea occurred during the first week of 
treatment with vilazodone. The ADRs were recorded as diarrhoea (32.5%) and nausea (24.7%) 
in vilazodone-treated patients, compared to diarrhoea (10.3%) and nausea (8.3%) in placebo-
treated patients (Croft et al., 2013). 
From the above studies and literature, it can be concluded that vilazodone is a safe and effective 
drug for patients with MDD and GAD. It offers promise as a novel antidepressant due to its’ 
tolerability in comparison to respective placebos and other antidepressants used in previous 
studies. Despite this, the long-term efficacy of vilazodone and a wider range of adverse effects 
should be established. Consistent pharmacovigilance and post-market surveillance are required 
for as long as vilazodone remains on the market. 
Chapter summary 
This chapter comprised of a literature review, highlighting the importance of 
pharmacovigilance for continued monitoring of drug safety.  This chapter also focused on ADR 
monitoring through pre-marketing clinical trials and post-marketing surveillance.  
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CHAPTER 3  
MANUSCRIPT 1 
Introduction 
This chapter describes the background, general findings and discussion of the results of the 
following objectives:  
 To quantify the adverse effects associated with vilazodone reported in VigiAccess, 
according to organ systems. 
 To compare the adverse effects reported in VigiAccess to the adverse effects indicated 
during the FDA approval process. 
 To compare the adverse effects reported in VigiAccess to adverse effects indicated on 
the PIL for Viibryd®. 
The chapter is in manuscript format in accordance with the College of Health Sciences 
guidelines for dissertation submissions at the University of KwaZulu-Natal (UKZN). The 
chapter has been written according to the author guidelines and has been submitted for 
publication to the Journal of Pharmacy Practice (see Annexure 2). The reference list is cited 
according to the instructions for authors as required by the Journal of Pharmacy Practice.  
The journal instructions to the author can be viewed in Annexure 3 or with the following link: 
https://us.sagepub.com/en-us/nam/journal-of-pharmacy-practice/journal201507#submission-
guidelines 
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ABSTRACT 
Background and Aim 
Vilazodone is a novel antidepressant having a selective serotonin (5-HT) reuptake inhibitor 
and 5-HT1A-receptor partial agonist profile. It was approved in 2011 by the U.S. Food and Drug 
Administration (FDA) for treating major depressive disorder in adults. The study aimed to 
review the adverse effects of vilazodone reported in the PIDM database, VigiAccess.  
Method 
Data on adverse effects reported for vilazodone was obtained from the database VigiAccess. 
VigiAccess provides an overview of adverse drug reactions reported according to body 
systems. Data was extracted from VigiAccess using Excel and analysed using descriptive 
statistics. The data collected was compared to the patient information leaflet (PIL) of Viibryd® 
and the FDA approval documents to determine adverse drug reactions reported post-marketing. 
Results 
A total of 9708 adverse events had been recorded on VigiAccess, which 6054 were not 
mentioned on the PIL and the FDA approval document. Most of the reports were received from 
the Americas and were for adult women aged 45-64 years (24%, n=1059). The highest total 
number of adverse events reported were for psychiatric events (19%; n=1889). This was 
followed by gastro-intestinal effects (18%; n=1839). The highest number of previously 
unrecorded adverse events was observed under psychiatric disorders (19%; n=1181) for 
anxiety (n=316), depression (n=208), hallucinations (n=168) and agitation (n=142). 
Conclusion 
The safety profile of a drug may evolve over time due to appearance of previously unrecorded 
adverse drug reactions during post-marketing surveillance. This study found several adverse 
drug reactions not recorded in documents emanating from clinical trials pre-marketing. 
Therefore, it is imperative that post-marketing surveillance continues for the duration of a 
drug’s use to ensure safety. 
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BACKGROUND 
Vilazodone is a novel antidepressant with a unique mechanism of action - it simultaneously 
acts as a selective serotonin reuptake inhibitor (SSRI) and a 5-HT1A-receptor partial agonist.
1  
The mechanism of action of vilazodone is related to its enhancement of serotonergic activity 
in the central nervous system (CNS) through selective inhibition of serotonin reuptake.2 
Vilazodone binds with high affinity to the serotonin reuptake site but not to the norepinephrine 
or dopamine reuptake site.2 The combined serotonin reuptake inhibition and buspirone-like 
anxiolytic mechanism of vilazodone contributes to this drug’s improved efficacy and 
tolerability compared to other antidepressants.2  
Vilazodone was approved in 2011 by the U.S. Food and Drug Administration (FDA) for the 
treatment of major depressive disorder in adults.1 Approval of a drug by the FDA implies that 
the perceived benefits outweigh its potential risks.3 Vilazodone presents with a spectrum of 
known adverse effects including diarrhoea, headache, nausea, vomiting and insomnia.4 Since 
drugs are approved based on clinical trial data, which involve relatively small numbers of 
controlled patients, post-marketing surveillance can further refine, confirm or deny the safety 
of a drug after it is used in the general population by large numbers of people who have a wide 
variety of medical conditions.5   
Post-marketing drug surveillance, also known as Phase IV of clinical trials, takes place after a 
drug has been approved by the medicine regulatory authority and is being marketed.5 The major 
part of post-marketing drug surveillance is related to the evaluation and monitoring of adverse 
drug reactions. Post-marketing surveillance provides valuable information on the use of drugs 
in special patient populations, which is not easily obtainable from pre-marketing studies.6 The 
post-market surveillance for adverse events begins immediately after the drug is available to 
the public and continues for as long as the drug is available on the market.6  
Pharmacovigilance (PV) is defined as the science and activities relating to the detection, 
assessment, understanding and prevention of adverse effects or any other drug-related 
problem.7 Post-marketing surveillance forms an important part of PV activities and the 
prompt reporting of any adverse reaction to a drug can lead to the early detection of side 
effects and reactions. The spontaneous reporting system for suspected ADRs represents the 
cornerstone of pharmacovigilance, because it allows for the rapid detection of potential 
alarm signals related to a drug’s use.8 However, spontaneous reporting shows several 
limitations, which are mainly related to under-reporting by health care professionals due to 
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a lack of time, quality of the reported data and the lack of information on drug exposure.8 
Healthcare professionals sometimes do not report ADRs because it is challenging to 
establish with certainty the causal relationship between the drug and adverse reaction.8 
Highlighting the need for continued monitoring and reporting of adverse effects due to the 
emergence of previously unknown ADRs will hopefully overcome these barriers to ADR 
reporting to enhance the post-marketing surveillance and the safety profile of medicines. 
 
This study reviewed the adverse effects of vilazodone post-marketing, via reports on the 
database VigiAccess, to highlight the contribution of and need for post-marketing surveillance 
of a drug.  
METHODOLOGY 
For this descriptive study, data on adverse effects reported for vilazodone was obtained from 
VigiAccess ( http://www.vigiaccess.org/). VigiAccess is a free-access database on side 
effects reported to the World Health Organization (WHO) Program for International Drug 
Monitoring (PIDM). This database presents ADRs in terms of body system, and provides 
demographics including, age, gender, and location per continent. Specific patient information 
is not provided in the database, thus underlying medical conditions, medication, and specific 
patient demographics are not available.  
Data was extracted from VigiAccess using Excel. The data was extracted according to body 
systems in the form of a table stating the number of previously unrecorded adverse drug 
incidents. Data was analysed using descriptive statistics. The data collected was compared to 
adverse drug reactions of vilazodone listed on the PIL 
(https://media.allergan.com/actavis/actavis/media/allergan-pdf-documents/product-
prescribing/2018-05-8-Viibryd(vilazodone)-USPI-Clean.pdf) and FDA approval documents 
(https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022567s000lbl.pdf) to 
determine post-marketing ADRs.  
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RESULTS 
At the time of the data extraction (25/08/19), a total of 9708 adverse events had been recorded 
on VigiAccess of which 6054 of these adverse events were not listed on the patient information 
leaflet (PIL) of Viibryd® and FDA approval document. Most of the reports were received from 
the Americas for adult patients aged 45-64 years (24%, n=1059). A high number of reports 
were also received for adult patients aged 18-44 years (20%, n=864). Sixty-eight percent of 
adverse events reported were observed in women. The highest number of ADR reports was 
seen in the year 2014, followed by 2012. 
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Table 1- Demographic data of ADR reports for vilazodone on Vigiaccess 
GEOGRAPHICAL DISTRIBUTION 
Continent Count  Percentage 
America 4358 99 
Asia 34 1 
Europe 3 0,068 
AGE GROUP DISTRIBUTION 
Age Group Count Percentage 
0 - 27 days 1 0,02275 
28 days to 23 months 6 0,1365 
2 - 11 years 13 0,2956  
12 - 17 years 51 1 
18 - 44 years 864 20 
45 - 64 years 1059 24 
65 - 74 years 309 7 
≥ 75 years 152 3 
Unknown 1940 44 
PATIENT SEX DISTRIBUTION 
Patient Sex Count Percentage 
Female 3005 68 
Male 1224 28 
Unknown 166 4 
ADR REPORTS PER YEAR 
Year Count Percentage 
2019 398 9 
2018 240 5 
2017 387 9 
2016 287 7 
2015 209 5 
2014 1814 41 
2013 134 3 
2012 926 21 
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Adverse events in VigiAccess were categorised according to 26 body systems. The highest 
percentage of adverse events reported were for psychiatric disorders (19%; n=1889) and 
specifically for insomnia (24%; n=455) and suicidal ideation (11%; n=205). This was followed 
by gastro-intestinal disorders (18%; n=1839), with the highest being diarrhoea (31%; n=582) 
and nausea (26%; n=477).  
Several adverse events that were not recorded in the PIL or FDA approval report was reported 
in VigiAccess (Table 2). The highest frequency was observed under psychiatric disorders 
(19%; n=1181) and included anxiety (26%; n=316), depression (17%; n=208), hallucinations 
(14%; n=168) and agitation (12%, n=142). 
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Table 2- Adverse events reported for vilazodone, not recorded on the FDA and PIL  
BODY SYSTEM NUMBER OF 
previously 
unrecorded types of 
ADRS 
MOST SIGNIFICANT 
PREVIOUSLY UNRECORDED 
ADRS 
Blood and lymphatic system 7 Anaemia (6 reports)   
Lymphadenopathy (6 reports) 
Cardiac Disorders 24 Tachycardia (16) 
Ear and Labyrinth Disorders 9 Tinnitus (48) 
Vertigo (25) 
Endocrine Disorders 6 Hyperthyroidism (2) 
Inappropriate ADHD secretion (2) 
Eye Disorders 47 Blurry Vision (69) 
Gastro-intestinal Disorders 359 Flatulence (38) 
Dyspepsia (33) 
Constipation (26) 
Hepatobiliary disorders 7 Hepatitis (3) 
Immune system disorders 56 Drug hypersensitivity (28) 
Infections and infestations 60 Sinusitis (8)  
Influenza (6) 
Investigations 421 Blood pressure increased (66)  
Heart rate increased (40) 
Metabolism and Nutrition disorders 65 Hyponatremia (14) 
Musculoskeletal and connective tissue 
disorders 
343 Muscle twitching (73)  
Muscle spasms (58) 
Neoplasms benign, malignant and 
unspecified (incl cysts and polyps) 
13 Neoplasm Malignant (2) 
Nervous System 232 Serotonin syndrome (82)  
Seizures (72) 
Pregnancy, puerperium and perinatal 
conditions 
5 Abortion Spontaneous (2) 
Psychiatric disorders 1181 Anxiety (316) 
Depression (208) 
Hallucination (168)  
Agitation (142) 
Renal and urinary disorders 70 Pollakiuria (14) 
Reproductive system and breast 
disorders 
73 Vaginal Haemorrhage (10) 
Respiratory, thoracic and mediastinal 
disorders 
151 Dyspnoea (63) 
Skin and subcutaneous tissue disorders 679 Pruritus (84) 
Alopecia (68) 
Rash (68) 
Vascular disorders 93 Hypertension (26) 
NUMBER OF PREVIOUSLY UNRECORDED ADR’s- 6054 
 
29 
 
DISCUSSION 
Over a period of 8 years (2012 – 2019) a total of 9708 ADRs were reported for vilazodone to 
the WHO PIDM. According to geographical data, most ADR reports emanated from the 
Americas, followed by Asia and Europe. This relates to the availability of the drug - vilazodone 
was released in the US (Americas) in 2011 prior to being marketed in Asia and Europe. No 
reports were submitted from Africa the drug is not currently available in any African country.  
In terms of patient demographics, reports were mostly submitted for ADRs experienced by 
adult (18 – 64 years) female patients. Vilazodone is an antidepressant mostly used by adult 
patients and rarely used in children below the age of 12.2 Due to the higher rate of use in adults, 
most adverse events would be observed in adults.  
In 2010 the global annual prevalence of depression was 5.5% in women and 3.2% in men, 
representing a 1.7-fold greater incidence in women.9 Women are more likely to experience 
specific forms of depression-related illnesses, including postpartum depression, 
postmenopausal depression and anxiety.9 Female hormonal fluctuations may be a trigger for 
depression making young women a greater risk for major depression and mental disorders 
globally.9  
Most of the ADRs recorded in VigiAccess, including known as well as previously unrecorded 
ADRs, were psychiatric events. A series of studies have shown that antidepressants produce 
changes in the central nervous system by modifying the recognition of basic emotions.10 While 
antidepressant effects occur as a result of excessive levels of serotonin and a downregulation 
of dopamine neurotransmission in neural circuits that regulate emotional processing, this may 
also contribute to emotional flattening and cognitive slowing resulting in anxiety, depression, 
hallucination and agitation in patients11, all of which were represented in the VigiAccess data. 
While these effects may occur in the first 3 months of treatment, evidence suggests that these 
may persist even after the symptoms of depression have improved11. The chronic elevation of 
serotonin levels due to a down-regulation of dopamine turn-over in circuits is associated with 
emotional blunting that may continue.10 For this reason, adverse effects such as anxiety and 
depression does not revert even after treatment with vilazodone. 
A significant number of gastrointestinal adverse events were also reported on VigiAccess. It is 
well known that serotonin plays a major role in the motor and sensory regulation of the 
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gastrointestinal tract (GIT).  Almost 95% of serotonin is found in the GIT, mainly in epithelial 
and glandular enterochromaffin cells.12 As a gastrointestinal hormone, serotonin is responsible 
for the regulation of smooth muscle motor activity and glandular secretion.13 It affects the 
gastrointestinal sensation of pain, nausea and vomiting by acting via specific receptors found 
in the GIT.12 Conventional functions of 5-HT in the gut involving intrinsic reflexes include 
stimulation of propulsive and segmentation motility patterns, epithelial secretion, and 
vasodilation.13 Drugs with effects on serotonin receptors such as vilazodone can therefore 
affect gastric motility. 
The majority of ADRs reported for the GIT, such as nausea, vomiting and diarrhoea, may be 
ascribed to vilazodone’s pharmacological mechanism of action.2 Vilazodone blocks the 
serotonin reuptake pump, desensitizes serotonin receptors and therefore increases serotonergic 
neurotransmission.14 Nausea, vomiting and diarrhoea results from stimulation of the central 5-
HT3 receptors and are one of the most common causes of treatment discontinuation associated 
with vilazodone.4 Activation of extrinsic vagal and spinal afferent fibres results in slowed 
gastric emptying, pain as well as nausea and vomiting.13  
The study found a significant number of ADRs reported in VigiAccess, not published in the 
PIL or the FDA approval document. It is therefore imperative that post-marketing 
surveillance continues for the duration the drug is being used by the public. Spontaneous 
reporting by healthcare professionals remain the mainstay of post-marketing surveillance. 
Post-marketing spontaneous reports of adverse drug reactions assist in detecting signals15, 
ultimately resulting in confirmation or disclaiming of an adverse effect with resultant 
appropriate action to be taken.  
 
Despite the importance of post-marketing surveillance and the need for spontaneous 
reporting to ensure efficient post-marketing surveillance, underreporting remains 
problematic.16 Low rates of ADR reporting are a significant healthcare problem and can 
delay regulatory actions taken to remove medicines with unacceptable safety profiles from 
the market.16 The most significant barrier to reporting ADRs as mentioned earlier is a lack 
of time by healthcare professionals.15 This can be addressed by simplifying the current 
reporting procedures and ensuring the continued monitoring of drugs.16 According to a key 
principle of pharmacovigilance, it is always better to report even a suspicion to generate an 
alarm in the interest of protecting public health.8  
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CONCLUSION 
Global drug safety depends on strong systems that monitor the quality of medicines, report 
their adverse effects, and provides accurate information for their safe use. The safety profile of 
a drug may evolve, causing changes in its’ clinical use and giving rise to previously unobserved 
adverse effects, necessitating post-marketing surveillance. 
This study found several adverse drug reactions only being observed after clinical trials.  More 
than half of the psychiatric adverse effects recorded on VigiAccess were not indicated on the 
PIL and FDA approval documentation, which clearly shows that continued monitoring of the 
safety of a drug is imperative. Health care professionals remain the primary source of ADR 
reporting by patients, and this problem can be addressed by ensuring the continuous monitoring 
and spontaneous reporting of drugs. 
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CHAPTER 4  
MANUSCRIPT 2 
Introduction 
This chapter describes the background, general findings and discussion of the results pertaining 
to the psychiatric adverse effects associated with the use of vilazodone in the form of a 
systematic review.  
The chapter is in manuscript format in accordance with the College of Health Sciences 
guidelines for dissertation submissions at the University of KwaZulu-Natal (UKZN). The 
systematic review manuscript protocol is registered on Open Science Framework: OSF DOI- 
10.17605/OSF.IO/2M7HY. The protocol has been written according to author guidelines and 
submitted for publication to the British Medical Journal (BMJ) Open (see Annexure: 4) 
The systematic review manuscript has been written according to author guidelines and will be 
submitted for publication to BMC Public Health. The reference list is cited according to the 
instructions for authors as required by BMC Public Health. The journal instructions to the 
author can be viewed in Annexure 5 or with the following link: 
https://bmcpublichealth.biomedcentral.com/submission-guidelines/preparing-your-
manuscript/review 
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ABSTRACT 
Background  
Vilazodone is a novel antidepressant that simultaneously acts as a selective serotonin 
reuptake inhibitor (SSRI) and a 5-HT1A-receptor partial agonist. It is approved for the 
management of Major Depressive Disorder (MDD). While the long-term efficacy and safety 
of vilazodone has been established, there are no systematic reviews focusing on its 
psychiatric side effects. This systematic review aims to synthesize evidence from studies 
evaluating the psychiatric adverse effects of vilazodone.  
Methods 
We will conduct a systematic review of randomized controlled trials (RCTs), prospective or 
retrospective cohort studies, case-control studies, cross-sectional studies, case series, and case 
reports that have evaluated the psychiatric adverse effects of vilazodone or comparative effects 
with other antidepressants. Two reviewers will independently search the following databases: 
Pubmed (Medline), Scopus, Web of Science, PsychInfo, Cochrane Central Register of 
Controlled Trials, ClinicalTrials.gov, and ProQuest Dissertation and Theses. Additional studies 
will be identified from Google scholar and references of studies. Study eligibility, quality 
assessment, and data extraction will be conducted before the narrative synthesis of study 
findings. Two reviewers will screen the primary studies for inclusion and perform the critical 
appraisal. Data will be analysed using SPSS software. Frequency tables will be used to 
summarise the data followed by a narrative synthesis. 
Ethics and dissemination  
As this will be a systematic review, without patient involvement, there will be no requirement 
for ethical approval. Findings will be disseminated widely through peer-reviewed 
publications.  
Protocol registration: OSF DOI- 10.17605/OSF.IO/2M7HY 
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Strengths and Limitations of the study 
 This systematic review protocol follows the Preferred Reporting Items for Systematic 
Review and Meta-Analysis Protocols (PRISMA) guidelines. 
 This systematic review addresses a gap in the current evidence-base by providing a 
comprehensive assessment of the psychiatric adverse effects which may influence the 
effectiveness of vilazodone as an antidepressant.  
 This review will include randomized controlled trials (RCTs), prospective or 
retrospective cohort studies, case-control studies, cross-sectional studies, case series, 
and case reports that have evaluated the psychiatric adverse effects of vilazodone or 
comparative effects with other antidepressants. 
 Non-English electronic databases will not be searched. This limitation may cause 
language bias. 
 There is the potential for a low and inconsistent quality in the reporting of process 
evaluations and in the number of articles related to the topic that are published 
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BACKGROUND AND RATIONALE OF THE STUDY 
A lot of information about the safety of a new drug is unknown when it is released onto the 
market. Unexpected adverse events or adverse drug reactions (ADRs) could arise at any 
time in the life cycle of a drug and could put the user at risk. ADRs have been reported as a 
significant clinical and public health problem causing nearly 5 to 35% hospitalization in 
both low-middle-income countries and high-income countries. 1 2 3 It is among the ten major 
causes of death in North American and Europe, as well as the rising cost of healthcare. 4 2 5 
 
Vilazodone is a novel antidepressant which simultaneously acts as a selective serotonin 
reuptake inhibitor (SSRI) and a 5-HT1A-receptor partial agonist.
6 Vilazodone was approved 
in 2011 by the U.S. Food and Drug Administration (FDA) for the treatment of major 
depressive disorder in adults.6 Vilazodone presents with various adverse effects that have 
mainly been identified during the pre-marketing phase trial of the drug.7 An assessment of 
VigiAccess (vigiaccess.org) found that several adverse events caused by vilazodone were 
not recorded in the patient information leaflet (PIL) or FDA approval report. The highest 
frequency of ADRs observed in VigiAccess was observed for psychiatric disorders (19%) 
and included anxiety (26%), depression (17%), hallucinations (14%), and agitation (12%). 
These ADRs necessitate the need for post-marketing surveillance to ensure the safety and 
efficacy of vilazodone throughout its’ use.  
 
Current theory suggests that sustained, long-term 5-HT1A receptor stimulation by 
vilazodone leads to a down-regulation of serotonin receptors so that, over time, serotonin 
release is no longer inhibited, thereby, causing psychiatric adverse effects.8 Therefore, these 
effects do not revert even after vilazodone treatment.9 
 
There are no systematic reviews that have gathered evidence of existing studies on the post-
marketing surveillance of reported psychiatric adverse effects of vilazodone. Therefore, 
there is good reason for the present systematic review protocol to map up existing evidence 
of psychiatric adverse effects and central nervous system effects related to the drug. 
Review Question 
1. What are the psychiatric adverse effects associated with the use of Vilazodone? 
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Objective  
The objective of this systematic review is to provide a synthesis of primary literature to: 
 To evaluate the psychiatric adverse effects associated with the use of vilazodone 
 To assess the risk factors of vilazodone psychiatric ADRs 
 To evaluate the need for post-marketing surveillance of vilazodone 
 
METHODS 
The Preferred Reporting Items for Systematic Reviews (PRISMA) guidelines will be followed 
(see Appendix 7). The protocol is registered on the Open Science Framework (OSF) and is 
available at https://doi.org/10.17605/OSF.IO/2M7HY  
 
Search strategy 
The search strategy will be used to find published articles in a three-phase protocol (see 
Appendix: 2). First, a limited search of Medline and Pubmed will be carried out. The text words 
and index terms contained in the titles and abstract of the articles obtained will be analysed. 
Secondly, all related keywords and index terms identified will be used in all the included 
databases. Thirdly, the reference section of selected articles will be checked for additional 
related studies. This review and meta-analysis will use multiple literature databases, including 
Pubmed (Medline), Proquest Psychology Journals, Web of Science, Taylor & Francis Online 
Journals, PsychInfo, and Wiley Online Library. Additional searches will be performed in 
Google Scholar. Since the international patent filing of vilazodone was done in 1999,10 our 
database search will be limited to publication dates from January 2000 to January 2020. Search 
limits will also be set to studies published in the English language because it is the only 
language of communication among the researchers and due to funding constraints.  Our 
systematic search will be built on three concepts: ‘vilazodone’, ‘adverse drug reaction’ and 
‘psychiatric’. MeSH terms and free texts like the keywords will be used to optimize our search 
on PubMed before translating to other databases. All the results of the literature search will be 
imported into the bibliographic software ‘Endnote X7’, and duplicates will be identified and 
removed by the primary reviewer (HK). 
The text words and index terms such as vilazodone, viibryd, depression, 5-HT1A, psychiatric 
disturbances, mental disorders, anxiety, depression, crying, sleep paralysis, and confusion will 
be used in each database. The search terms will be combined using the Boolean operators 
‘AND’ and ‘OR’ as indicated in Appendix 2.11 
40 
 
ELIGIBILITY CRITERIA 
The Population, Intervention, Comparison, Outcome, and Study design (PICOS) framework 
will be used to determine the eligibility of primary studies (see Appendix: 3). 
Population 
We will include studies with adolescents (12-18 years) and adults aged 18 years and older that 
report psychiatric adverse effects of vilazodone. Although we expect most studies to be on 
depression and anxiety disorders, we will not limit study choice to any medical indication 
provided. 
 
Intervention 
Vilazodone (irrespective of dose and duration). 
 
Comparison 
Placebo, no drug exposure or other antidepressants. 
 
Outcome 
The incidence and risk factors of psychiatric adverse effects associated with the use of 
vilazodone will be the outcomes of interest. 
 
Study design 
 
We will include all study designs, including randomized controlled trials (RCTs), prospective 
and retrospective cohort studies, case-control studies, cross-sectional studies, case series, and 
case reports.  Reviews, meta-analysis, editorials, conference abstracts, and presentations will 
be excluded. If multiple papers connected to a study have been published, we will either 
combine the results or select the paper with the largest sample size. 
STUDY SELECTION 
Two reviewers (HK and HM) will independently screen all titles and abstracts of the retrieved 
articles for inclusion/exclusion based on the eligibility criteria. The studies that meet the 
inclusion criteria will then undergo full-text screening. Where disagreements occur on 
inclusion/exclusion, a resolution will be by discussion, and a third reviewer (KM) if required. 
41 
 
Abstracts not providing enough information regarding the inclusion/exclusion criteria will be 
selected for full-text evaluation. We may contact the authors of primary studies to seek 
clarification or to obtain additional data. Reasons for study exclusion will be noted and 
described in a PRISMA flowchart according to PRISMA guidelines.12  
 
SCREENING AND DATA EXTRACTION 
This systematic review will be carried out by three reviewers. All titles and abstracts of the 
retrieved articles will be independently screened by two reviewers independently to identify 
eligible studies for this systematic review, according to the inclusion criteria. Where 
disagreements occur on inclusion/exclusion, the third reviewer will resolve. The studies that 
do not meet the eligibility criteria will be excluded. Abstracts not providing enough information 
regarding the inclusion/exclusion criteria will be selected for full-text evaluation. 
Inconsistencies in data collection will be solved by consensus. Concurrent and contradictory 
relationships between categories will be identified, and research findings will be discussed.   
 
A standardized data extraction form will be used to extract data from the included studies. It 
will be developed considering the guide provided by the Cochrane Collaboration about content 
and structure.11 This data extraction form will be piloted before use. The data extraction form 
will include authors, year, country, study title, study period, reference, method characteristics 
(study size, study design, study objective or research question, study participant characteristics, 
study setting, method of assessment, statistical analyses, the treatment used and associated 
psychiatric adverse effects caused) and key findings, conclusion, a summary of study strengths, 
and limitation. Any changes made during the data extraction process will be reported in the 
final manuscript. Detailed data extraction will be done using Microsoft Word tables or 
Microsoft Excel spreadsheets to summarise the data from the selected studies. Data will be 
extracted by the main reviewer (HK) and checked by the other reviewers, with disagreements 
resolved by consensus. 
 
QUALITY ASSESSMENT 
Two reviewers will independently examine each selected article to reduce bias. The quality of 
randomized controlled trials (RCTs), cross-sectional studies, case series, and case reports will 
be assessed using tailor-made tools from the Joanna Briggs Institute (JBI).13 The results of this 
appraisal will be used to show the possibility of bias in the design, conduct, and analysis of 
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each study. Any conflicts over the assessment of quality will be resolved by consensus between 
reviewers. 
 
DATA SYNTHESIS AND DESCRIPTIVE ANALYSIS 
The data extracted will be imported into SPSS Software for analysis. This includes focusing 
on extracting insights from the data and sorting the findings into categories of thought. Data 
will be summarized using text and tables. Frequency tables will summarize categorical data, 
including sample characteristics, patient characteristics and psychiatric adverse effect 
outcomes. Psychiatric adverse effects found from selected articles will be listed according to 
preferred terms based on the most commonly used coding system, the Medical Dictionary for 
Regulatory Activities (MedDRA)14 (see Appendix 5). Using these terms, the impact of 
psychiatric adverse effects on vilazodone will be described. A narrative synthesis will 
describe and discuss the outcomes.  
ETHICS AND DISSEMINATION 
This evidence-based systematic review will summarise the relevant information on the 
association of vilazodone use and psychiatric adverse effects. Because the data used for this 
systematic review will be exclusively extracted from published studies, ethical approval and 
informed consent of patients will not be required. The results and findings of this study will be 
submitted and published in a scientific peer-reviewed journal. The findings from this study 
could be useful for assessing the psychiatric adverse effects with the use of vilazodone for 
prevention in the future. 
 
PATIENT AND PUBLIC INVOLVEMENT 
Patients were not directly involved in the design of this study. As this is a protocol for a 
systematic review and no participant recruitment will take place, their involvement in the 
dissemination of findings to participants was not applicable. 
 
AMENDMENTS 
Any amendments to this protocol will be documented regarding saved searches and analysis 
methods, which will be recorded in bibliographic databases, EndNote for data collection and 
synthesis. Important protocol amendments post registration will be recorded and included in 
dissemination. 
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DEALING WITH MISSING DATA 
Authors of primary studies will be contacted for additional information if relevant data is not 
reported in published manuscripts. 
 
DISCUSSION 
This systematic review will synthesize research evidence to establish the psychiatric adverse 
effects associated with the use of vilazodone. Psychiatric adverse effects caused by SSRI’s 
have received little attention in clinical studies and are not listed in the literature as part of its’ 
known or expected adverse effects.15 The undetected ADRs of vilazodone assessed in the 
manuscript necessitate the need for post-marketing surveillance to ensure the safety and 
efficacy of the drug throughout its’ use. Future research should more specifically and 
systematically examine these psychiatric adverse effects as they come into the market. 
Therefore, we will conduct a systematic review and meta-analysis, if possible, to show a 
general view of the current literature, as well as further improve research regarding the 
psychiatric adverse effects associated with vilazodone.  
Potential limitations are inherent in conducting systematic reviews and meta-analyses: 
publication bias, information bias, weak statistical analyses, poor methodological quality, and 
inadequate reporting of methods and findings of the included studies. Another limitation might 
be the restriction of the analysis to studies published in English. Therefore, it is important to 
synthesise the information available in the manuscripts included adequately. This task will be 
conducted independently by two reviewers, and disagreements will be resolved by consensus. 
Likewise, the Cochrane Collaboration Handbook recommendations will be followed.  
In summary, due to a lack of agreement and conclusions about the relationship between 
vilazodone and psychiatric adverse effects, it seems logical and important to carry out a 
systematic review and meta-analysis to make patients and health care professionals more aware 
of these effects that will contribute to the drug safety. 
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Psychiatric adverse effects associated with the use of Vilazodone- a systematic review 
ABSTRACT  
Background: Vilazodone is a novel antidepressant used to treat Major Depressive Disorder 
(MDD). Available literature suggests that the efficacy and safety of vilazodone-associated 
psychiatric adverse effects have not yet been systematically assessed and described. To add to 
the knowledge about the psychiatric adverse effects caused by vilazodone, this study provides 
a systematic review of all available research literature and aims to provide a critical summation 
of present findings. The aim of this study is to provide a critical overview of the literature on 
the psychiatric adverse effects caused by vilazodone from January 2000 to January 2020, 
highlighting the effects, consistencies, knowledge gaps, current theories, and limitations of 
available understandings.   
Method: We searched electronic databases and reference lists for studies published between 
January 2000 to January 2020. A systematic review of the literature on psychiatric adverse 
effects associated with vilazodone was conducted using the Cochrane Framework. Two 
reviewers screened the primary studies for inclusion and performed the critical appraisal. Data 
was analysed using SPSS software. Frequency tables were used to summarise the data followed 
by a narrative synthesis. 
Findings: From an initial search of 124 articles, a total number of 7 full texts, that met the 
inclusion criteria, were included for the review. Several psychiatric adverse effects were found 
to occur with the use of vilazodone. The findings of this study suggested that these common 
psychiatric adverse effects associated with the use of vilazodone are not included in the FDA 
registration document and patient information leaflet (PIL). 
Conclusions: Vilazodone has a wide range of adverse psychiatric effects as apparent from 
reviewing published clinical trials.  More considerable attention in research should be given to 
a broader range of psychiatric adverse effects associated with vilazodone, and further detailed 
clinical trials are required to establish the safety profile. The limited amount of evidence from 
researched articles shows that there is a lack of studies that can prove the safety of vilazodone 
associated with psychiatric adverse effects. 
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INTRODUCTION 
Background 
Adverse drug reactions (ADRs) can affect patients irrespective of age or gender, ultimately 
impacting on morbidity and mortality [1]. ADRs have become a major global health problem 
that needs to be addressed [2]. According to a study, ADRs are identified as the 4th – 6th prime 
cause of death in the United States with the contribution of more than 100 000 deaths annually 
[3].  
Vilazodone is a relatively new drug that was released on to the market in 2011, sold under the 
brand name Viibryd, used to treat Major Depressive Disorder (MDD) [4]. Currently, there are 
numerous effective antidepressants on the market that have been available much longer than 
vilazodone.  Vilazodone has an advantage because it offers a dissimilar mechanism that 
produces remission of depressive symptoms [5]. Vilazodone simultaneously acts as an SSRI 
and a 5-HT1A-receptor partial agonist and enhances serotonergic activity in the CNS through 
selective inhibition of serotonin reuptake [4].  
Over the years, several other adverse effects, including diarrhoea, headache, nausea, vomiting, 
and insomnia, have been identified with the use of vilazodone [6]. However, being a relatively 
new drug, it is not clear if all adverse effects have been identified. In recent times, new warnings 
were reported of the drug indicating the risk of psychiatric adverse effects such as worsening 
depression and the emergence of suicidal ideation [7]. More than half of the adverse effects 
recorded on the WHO site, VigiAccess, were not indicated on the patient information leaflet 
(PIL) and FDA approval documentation. The highest frequency of these undetected adverse 
effects was observed under psychiatric disorders, clearly indicating the need for continued 
monitoring of the safety aspects post-marketing.  
Psychiatric adverse effects caused by SSRI’s have received little attention in clinical studies 
and is not listed in the literature as part of the known or expected adverse effects [8]. 
Information about an antidepressants’ adverse effects at the time of marketing is generated only 
from pre-marketing trials and studies [6]. This may be due to the failure of clinical studies to 
systematically assess psychiatric adverse effects [9]. Post-marketing studies and monitoring 
will provide more information about a drugs’ effects on patients in clinical contexts.  
The purpose of this study was to evaluate the psychiatric adverse effects associated with the 
use of vilazodone and evaluate the factors that have been hypothesized as being responsible for 
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these effects. The study further evaluates the need for post-marketing surveillance. To add to 
the knowledge about the psychiatric adverse effects caused by vilazodone, this study provides 
a systematic review of all available research literature on the associations between the 
variables. 
 
METHODS 
Study Protocol 
The Preferred Reporting Items for Systematic reviews and Meta-analysis (PRISMA) guidelines 
were followed in conducting and reporting this review [10]. (for PRISMA checklist see 
Appendix: 7).  
 
Search strategy 
The search strategy was used to find published articles in a three-phase approach (see Appendix 
4). First, a limited search of Pubmed (Medline) was carried out. The text words and index terms 
contained in the titles and abstract of the articles obtained were analysed. Secondly, all related 
keywords and index terms identified were used in all the included databases. Thirdly, the 
reference section of selected articles was checked for additional related studies. We performed 
a systematic literature search in March 2020 using multiple literature databases, including 
Pubmed (Medline), Proquest Psychology Journals, Web of Science, Taylor & Francis Online 
Journals, PsychInfo, and Wiley Online Library. Additional searches were performed in Google 
Scholar. Studies were limited to publication date from January 2000 to April 2020 as the patent 
of vilazodone for registration was only received in 2011. Studies were also limited to the 
English language because it is the only language of communication among the researchers. 
Filters were set to English, human studies and studies in adolescents (12 years and older) and 
adults (18yrs and older). Reference checking of included articles was also done to capture 
missing primary articles as a result of indexing errors [see supplementary material, table 2, for 
search details]. The bibliographic software (Endnote), was used for the data management of 
retrieved references. All the results of the literature searches were imported into the Endnote 
program and duplicates were removed by the primary reviewer (HK). 
The text words and index terms such as vilazodone, viibryd, depression, 5-HT1A, psychiatric 
disturbances, mental disorders, anxiety, depression, crying, sleep paralysis, and confusion 
were used in each database. The search terms were combined using ‘AND’ and ‘OR’ as 
indicated in Appendix 2. 
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Study Eligibility 
The PICOS framework was used to set criteria to identify potential studies (7). The inclusion 
criteria were study population (adolescents aged >12 and adults aged >18 years who reported 
psychiatric adverse effects with the use of vilazodone), intervention (vilazodone irrespective 
of dose and duration), comparator (may include studies comparing psychiatric adverse effects 
and outcomes with vilazodone and other antidepressants), outcomes (psychiatric adverse 
effects caused with the use of vilazodone), and study design (randomized controlled trials 
(RCTs), case reports of vilazodone, cross-sectional studies and cohort studies). We excluded 
studies if they were not published in English, published before 2000, were not primary studies, 
and if they did not report any psychiatric effects and outcomes.  
 
Study Selection 
All articles were retrieved independently from the search of the electronic databases by HK 
and HM and then exported to EndNote. The articles were reported using the PRISMA 
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram [10]. 
Duplicates were identified and removed using EndNote. HK and HM independently reviewed 
all titles and abstracts to determine eligibility based on set criteria. With this, HK and HM then 
evaluated full texts of the articles identified for their final eligibility for data extraction. All 
disagreements were resolved by discussion or consultation with a third reviewer KM.  
 
Quality Assessment and Data Extraction 
HK and HM critically evaluated the quality of selected articles by employing the Joanna Briggs 
Institute (JBI) critical appraisal checklist for analytical cross-sectional studies, JBI critical 
appraisal checklist for cohort studies, the JBI critical appraisal tool for case series/reports and 
JBI critical appraisal tool for randomized controlled trials [11]. The articles were then ranked 
based on their quality scores as less than 50% (low-quality), 50% to 75% (moderate-quality 
studies), or greater than 75% (high-quality studies). We did not predefine any study exclusion 
based on quality criteria. The results of this appraisal were used to show the possibility of bias 
in the design, conduct and analysis of each study. We employed a predesigned data extraction 
form prepared in a Microsoft Excel® sheet. HK and KM piloted the data extraction form to 
ensure completeness and clarity. The following data were extracted: bibliographic information, 
study characteristics, participants’ characteristics, treatment information, description of 
psychiatric adverse effects and outcome of interest. All disagreements in the course of 
extraction were resolved by discussion and consensus. 
52 
 
Data Synthesis 
Data was imported into SPSS Software for analysis. Frequency tables summarized categorical 
data, including sample characteristics, patient characteristics and psychiatric adverse effect 
outcomes. Psychiatric adverse effects found from selected articles were listed according to 
preferred terms based on the most commonly used coding system, the Medical Dictionary for 
Regulatory Activities (MedDRA) [12] (see Appendix: 5). Using these terms, the impact of 
psychiatric adverse effects on vilazodone were then described. A narrative synthesis was then 
done to describe and discuss the outcomes.  
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Figure: 1 PRISMA FLOW DIAGRAM (Moher, Liberati, Tetzlaff & Altman, 2009)  
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SEARCH FINDINGS AND ANALYSIS  
Search results 
The data collection process for this systematic review began on the 26th of March 2020. The 
process involved a four-part search that yielded a total of 124 articles.  As shown in the 
PRISMA flow chart (see Figure: 1), upon the removal of any duplicates, the articles available 
were then reduced to n=102. The abstracts of each article were screened according to the 
abovementioned search criteria, following which n=58 texts were excluded. This left a total of 
52 potentially eligible full texts to be assessed.  A total of 37 articles were excluded from the 
reviewed full-texts due to the repetition of articles or article irrelevance. Thus, the final number 
of full-text articles included in this review was n=7.  
Quality assessment/risk of bias  
Using the JBI levels of evidence, one study [9] in this review is a cross-sectional study. One 
study [13] is a cohort study. Five studies in this review are RCTs [14-18]. Appraisal of 
individual studies using the JBI critical appraisal method is shown in the supplementary 
information (see Appendix: 6, Table 6A-C). To summarize, the cross-sectional studies were of 
high quality (100%). The prospective cohort studies were of moderate quality studies (50-
75%). All RCTs were of high quality (>75%).  
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ANALYSIS OF FINDINGS 
Study Characteristics  
The articles that were selected were all published in the years between 2009-2017, with 
majority of the studies conducted only after vilazodone was released on to the market in 2011 
(n=6). All included studies were published articles including randomized controlled trials 
cohort studies (RCTs) (n=5), open-label cohort studies (n=1), and cross-sectional studies (n=1) 
that were selected and included in this review. Of the RCTs (n=5), there were (n=3) phase IV 
trials and phase III trials conducted (n=2). Most of the studies took place over 8-10 weeks 
(n=6). The dose range for all studies included vilazodone 40mg- 10mg taken once daily for 
seven days, 20mg for the next seven days, then increased to 40mg for the duration of the study.  
Demographic and patient characteristics 
All studies took place in the USA, also being the country with the highest rate of use of 
vilazodone. The main objective of all the included studies was completed to evaluate the safety 
and efficacy of vilazodone for either the treatment of Major Depressive Disorder (MDD) or 
Generalized Anxiety Disorder (GAD). Most of the studies (n=6) included a population age 
group of between 18-70 years. The mean age for all included studies was 38 years.  The mean 
percentage for the race group, which accounted for the highest population of users were white 
(76%). The mean percentage of users was highest for females (65%), followed by males (35%). 
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Table 1- Study characteristics of included studies 
Studies 
 
Design Groups (n) Duration Functional 
Tests 
Dose range Summary 
of main 
objective 
Inclusion 
Population 
Summary 
of findings 
(psychiatric 
adverse 
effects) 
Croft et 
al., 2014 
RCT 
Double 
blind 
Phase IV 
n = 797 
Vilazodone  
40mg = 253 
Vilazodone 
20mg =292 
Placebo= 
252 
8 weeks C-SSRS 
MADRS 
CGI-S 
HAM-A 
Vilazodone 
10mg once 
daily for 
seven days, 
20mg for the 
next seven 
days and 
40mg for the 
duration of 
the study 
To assess 
the 
efficacy, 
safety and 
tolerability 
of 
vilazodone 
in patients 
with MDD 
Adults with 
MDD who had 
an ongoing 
major 
depressive 
episode lasting 
≥8 weeks and 
up to 12 
months, and 
had an 
MADRS total 
score ≥26 
Anxiety, 
irritability, 
depression 
and suicidal 
ideation  
Mathews 
et al., 2015 
RCT 
Double 
blind 
Phase: IV 
n= 1133 
Vilazodone  
40mg= 291 
Citalopram  
40mg= 289 
Placebo= 
290 
10 weeks C-SSRS 
MADRS 
HAM-A 
CGI-I 
CGI-S 
Vilazodone 
10mg once 
daily for 
seven days, 
20mg for the 
next seven 
days and 
40mg for the 
duration of 
the study 
To 
evaluate 
the safety 
and 
efficacy of 
vilazodone 
20-40mg 
in patients 
with MDD 
Adults with 
MDD who had 
an ongoing 
major 
depressive 
episode lasting 
≥8 weeks and 
up to 12 
months, and 
had an 
MADRS total 
score ≥26 
Suicidal 
ideation  
Robinson 
et al., 2015 
Open 
Label 
multicentre 
safety trial 
cohort 
study 
n = 599 52 weeks MADRS 
CGI 
C-SSRS 
Vilazodone 
titrated from 
10-40mg 
over ten 
days 
To assess 
the safety 
and 
tolerability 
of 
vilazodone 
in patients 
with MDD 
Adult patients 
with a 17-item 
Hamilton 
Rating Scale 
for Depression 
score of 18 or 
greater 
received 
vilazodone 
according to a 
fixed-titration 
schedule to 
reach a dose 
of 40 mg/d 
continued up 
to 1 year. 
Abnormal 
dreams, 
anxiety and 
suicidal 
ideation 
Gommoll 
et al., 2015 
RCT 
Double 
blind 
Phase: 3 
n= 673 
Vilazodone  
40mg= 225 
Vilazodone  
20mg= 227 
Placebo= 
221 
10 weeks C-SSRS 
HAM-A 
CGI-I 
CGI-S 
 
Vilazodone 
20-40 mg 
To 
evaluate 
the safety 
and 
efficacy of 
vilazodone 
in patients 
with GAD 
Participants 
with HAMA 
total score 
≥20, HAMA 
items 1 and 2 
scores ≥2 and 
CGI-S score 
≥4 
Abnormal 
dreams and 
suicidal 
ideation 
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Durgam et 
al., 2016 
RCT 
Double 
blind 
n= 529 
Vilazodone  
15mg= 175 
Vilazodone  
30mg= 180 
Placebo= 
174 
10 weeks C-SSRS 
CDRS-R 
CGI-S 
Vilazodone 
15-30mg 
To 
evaluate 
the safety, 
efficacy 
and 
tolerability 
in 
adolescent 
patients 
with MDD 
Patients aged 
12–17 years 
with a 
diagnosis of 
MDD for a 
minimum of 6 
weeks with the 
Children’s 
Depression 
Rating Scale–
Revised 
(CDRS-R) 
total score C 
40 and a 
Clinical 
Global 
Impressions–
Severity (CGI-
S) score C 4. 
Nightmares, 
suicidal 
ideation, 
depression, 
suicidal 
attempt, 
anxiety, 
depressive 
symptoms, 
impulsive 
behaviour, 
irritability, 
mental status 
change, 
suicidal 
ideation and 
suicidal 
behaviour 
 
Khan et 
al., 2009 
RCT 
Double 
blind 
Phase: III 
n= 481 
Vilazodone  
40mg= 235 
Placebo= 
233 
8 weeks HAM-A 
MADRS 
CGI-I 
CGI-S 
HDRS 17 
HDRS 21 
HARS  
Vilazodone 
10mg once 
daily for 
seven days, 
20mg for the 
next seven 
days and 
40mg for the 
duration of 
the study 
To 
evaluate 
the safety 
of 
vilazodone 
in patients 
with MDD 
Adults with 
MDD who had 
an ongoing 
major 
depressive 
episode lasting 
≥4 weeks and 
≤2 years, and 
had an HDRS-
17 total score 
≥22 
Abnormal 
dreams 
Hughes et 
al., 2017 
Cross 
Sectional 
Study 
n= 3243 
Escitalopram
= 2359 
Vilazodone= 
394 
Duloxetine= 
305 
Vortioxetine
= 185 
 N/A Vilazodone 
10mg 
To 
examine 
the adverse 
effects 
among 
online 
users and 
reviews of 
two older 
and two 
newer 
antidepress
ants 
Included 
article based 
on online user 
reviews for 4 
antidepressant
s from three 
websites: the 
professional 
health portals 
WebMD and 
Everyday 
Health, and 
AskAPatient.  
Abnormal 
dreams, 
agitation, 
aggression 
or increased 
anger, 
aggravated 
depression, 
crying, 
anxiety, 
confusion, 
depersonaliz
ation, 
emotional 
numbing, 
sleep 
paralysis, 
suicidal 
ideation or 
attempt 
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Table 2- Demographic and patient characteristics 
 
 
 
 
 
 
 
 
 
 
 
Author Year Publication Country Age Mean 
Age 
Race Gender 
Croft et al., 
2014 
2015 Article USA 18-70 
years 
39 
years 
80% 
white 
68% 
female 
32% male 
Mathews et 
al., 2015 
2015 Article USA 18-70 
years 
41 
years 
71% 
white 
57% 
female 
43% male 
Robinson et 
al., 2015 
2015 Article USA 18-70 
years 
42 
years 
80% 
white 
68% 
female 
32% male 
Gommoll et 
al., 2015 
2015 Article USA and 
Mexico 
18-70 
years 
40 
years 
81% 
white 
69% 
female 
31% male 
Durgam et 
al., 
2016 
2016 Article USA 12-17 
years 
15 
years 
67% 
white 
59% 
female 
41% male 
Khan et al., 
2009 
2009 Article USA 18-70 
years 
41 
years 
77% 
white 
59% 
female 
41% male 
Hughes et 
al., 2017 
2017 Article USA 19-75 
years 
47 
years 
 77% 
female 
23% male 
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Table 3- Psychiatric adverse effect outcomes of vilazodone from reviewed studies 
 
PSYCHIATRIC 
ADVERSE EFFECT 
GROUPS (n) 
Croft et al., 2014 
 Vilazodone 40mg  
n = 255 (%) 
Placebo  
n= 253 (%) 
Anxiety 2 (0.8) 1 (0.4) 
Irritability 1(0.4) 2 (0.8) 
Depression 0 2 (0.8) 
Suicidal ideation based 
on C-SSRS scale 
19% 21% 
Durgam et al., 2016 
 Vilazodone 
15mg  
n=175 (%) 
Vilazodone 
30mg  
n=180 (%) 
Placebo 
n=171 (%) 
Nightmare 0 2 (1.1) 0 
Suicidal ideation 2 (1.1) 2 (1.1) 1 (0.6) 
Depression 3 (1.7) 1 (0.6) 0 
Suicidal attempt 0 1 (0.6) 0 
Anxiety 1 (0.6) 0 0 
Depressive symptoms 1 (0.6) 0 1 (0.6) 
Impulsive behaviour 0 0 1 (0.6) 
Irritability 1 (0.6) 0 0 
Mental status change 1 (0.6) 0 0 
Suicidal ideation based 
on C-SSRS scale  
36% 31.1% 33% 
Suicidal behaviour 
based on C-SSRS scale 
1.1% 1.1% 1.8% 
Gommoll et al., 2015 
 Vilazodone 20-40mg  
n=200 (%) 
Placebo  
N=198 (%) 
Abnormal dreams 10 (5) 3 (1.5) 
Suicidal ideation based 
on C-SSRS scale 
6% 8% 
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Hughes et al., 2017 
 Duloxetine 
n=305 (%) 
Escitalopram 
n=2,359 (%) 
Vilazodone 
n=394 (%) 
Vortioxetine 
n=185 (%) 
 119 (39.0) 930 (39.4) 225 (57.1) 76 (41.1) 
 Abnormal dreams 18 (5.9) 135 (5.7) 101 (25.6) 5 (2.7) 
 Agitation  10 (3.3) 70 (3.0) 30 (7.6) 20 (10.8) 
 Aggression or 
increased anger  
8 (2.6) 56 (2.4) 42 (10.7) 10 (5.4) 
 Aggravated depression, 
crying 
26 (8.5) 123 (5.2) 46 (11.7) 20 (10.8) 
 Anxiety  27 (8.9) 240 (10.2) 53 (13.5) 29 (15.7) 
 Confusion 16 (5.2) 100 (4.2) 25 (6.3) 10 (5.4) 
 Depersonalization 14 (4.6) 157 (6.7) 13 (3.3) 5 (2.7) 
 Emotional numbing 25 (8.2) 253 (10.7) 16 (4.1) 11 (5.9) 
 Sleep paralysis 0 (0) 1 (0) 20 (5.1) 0 (0) 
 Suicidal ideation or 
attempt 
18 (5.9) 62 (2.6) 20 (5.1) 8 (4.3) 
Khan et al., 2009 
 Vilazodone 40mg (235) Placebo (233) 
Abnormal dreams 14 (6.0) 4 (1.7) 
Mathews et al., 2015 
 Vilazodone 
20mg  
n=288 (%) 
Vilazodone 
40mg  
n=284 (%) 
Citalopram 
40mg  
n=280 (%) 
Placebo 
n=281 (%) 
Suicidal ideation based 
on C-SSRS scale 
17.4% 18.1% 16.3% 24.2% 
Robinson et al., 2015 
 Vilazodone 40mg  
n=599 (%) 
Abnormal dreams 62 (10.4) 
Anxiety 36 (6.0) 
Suicidal Ideation 5 (0.8) 
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Table 4- Summary of psychiatric adverse effects from reviewed articles 
Psychiatric Adverse Effects Literature 
Abnormal dreams 
 
Hughes et al., 2017  
Gommoll et al., 2015 
Khan et al., 2009 
Robinson et al., 2015 
Agitation  Hughes et al., 2017 
Aggression or increased anger  Hughes et al., 2017  
Aggravated depression, crying Hughes et al., 2017 
Durgam et al., 2016 
Irritability Croft et al., 2014 
Durgam et al., 2016 
Anxiety  Hughes et al., 2017  
Croft et al., 2014 
Durgam et al., 2016 
Robinson et al., 2015 
Confusion  Hughes et al., 2017 
Depersonalization  Hughes et al., 2017 
Emotional numbing  Hughes et al., 2017 
Sleep paralysis  Hughes et al., 2017  
Suicidal ideation or attempt  Hughes et al., 2017  
Robinson et al., 2015 
Mathews et al., 2015 
Gommoll et al., 2015 
Croft et al., 2014 
Durgam et al., 2016 
Alterations in mental status Durgam et al., 2016 
Nightmares Durgam et al., 2016 
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Psychiatric adverse effect outcomes 
A double-blind placebo-controlled study was conducted over ten weeks by Durgam et al., to 
test the efficacy of vilazodone amongst adolescent patients aged 12-17 years old. Adverse 
effects that led to the discontinuation of the drug included nightmares (vilazodone, n = 2; 
placebo, n = 0), suicidal ideation (vilazodone, n = 4; placebo, n = 1), and depression 
(vilazodone, n = 4; placebo, n = 0). In the study by Croft et al., anxiety (0.8%) was recorded 
with vilazodone use, higher than the placebo (0.4%). Irritability was also recorded but was 
lower than the placebo (vilazodone= 0.4%, placebo=0.8%). 
Khan et al. reported that abnormal dreams recorded with the use of vilazodone (6%) were much 
higher than with the use of the placebo (1.7%). In the article by Gommoll et al., abnormal 
dreams (5%) were reported higher with the use of vilazodone (5%) in comparison to the use of 
the placebo (1.5%). In the open- label cohort study by Robinson et al., psychiatric adverse 
effects such as abnormal dreams (10.4%), anxiety (6%), and suicidal ideation (0.8%) were also 
recorded with the use of vilazodone.  
According to the article by Hughes et al., online user reviews of two older antidepressants, 
escitalopram and duloxetine, and 2 newer antidepressants, vilazodone and vortioxetine, with 
few completed clinical studies and less post-marketing experience, were studied for differences 
in their adverse effect profiles [9]. The final sample consisted of 3,243 user reviews on the four 
drugs: escitalopram, n=2,359 (72.7%); vilazodone, n=394 (12.1%); duloxetine, n=305 (9.4%); 
vortioxetine, n=185 (5.7%) from three popular health websites [9]. Patients reported 57% of 
psychiatric adverse effects with the use of vilazodone, followed by 41.4% of gastrointestinal 
and 28.4% of sleep effects [9]. Psychiatric adverse effects demonstrated moderate to substantial 
relationships with patients’ satisfaction for vilazodone, whereas gastrointestinal, metabolic, or 
sexual adverse effects were minimally related [9]. Vilazodone was reported by 6-20% of users 
to cause insomnia. Vilazodone users reported the highest rates of abnormal dreams (25.6%), 
aggression and anger (10.7%), aggravated depression and crying (11.7%), sleep paralysis 
(5.1%), agitation (7.6%) and confusion (6.3%) in comparison to the other antidepressants. 
Patients described symptoms of feeling irritable with anger spells, crying, anger, and sleep 
paralysis that occurred with the use of vilazodone [9]. Worsened anxiety was a highly reported 
psychiatric adverse effect among the users of vilazodone. Patients reported 57% of psychiatric 
adverse effects with the use of vilazodone, followed by 41.4% of gastrointestinal and 28.4% of 
sleep effects. Psychiatric adverse effects demonstrated moderate to substantial for vilazodone. 
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Based on C-SSRS findings, in the article by Durgam et al., reports of suicidal ideation (placebo, 
33.3%; vilazodone 15 mg/day, 36.0%; vilazodone 30 mg/day, 31.1%) and suicidal behaviour 
(placebo, 1.8%; vilazodone 15 mg/day, 1.1%; vilazodone 30 mg/day, 1.1%) were recorded. 
Suicidal ideation with the use of vilazodone 15mg, was recorded as the highest in comparison 
to the placebo. The incidence of suicidal ideation during double-blind treatment in the article 
by Mathews et al., was also determined by the C-SSRS scale. The results showed suicidal 
ideation as being higher in the placebo group (24.2%) relative to the active treatment groups 
(vilazodone 20 mg/day, 17.4%; vilazodone 40 mg/day, 18.1%; citalopram, 16.3%). In the 
article by Gommoll et al., C-SSRS-rated suicidal ideation was also reported more often among 
patients in the placebo group (8%) compared with the vilazodone group (6%). Suicidal 
ideation, according to the C-SSRS scale in the study by Croft et al., was recorded as 19% with 
the use of vilazodone and 21% with placebo use. 
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DISCUSSION OF RESULTS 
Vilazodone was approved by the U.S. Food and Drug Administration (FDA) for the treatment 
of MDD in adults in 2011 [4]. Thus, reviewed articles were mainly published over the period 
between 2012 - 2017 and clinical trials mostly in the Americans.  According to statistics, 
antidepressants are one of the most commonly prescribed medications in the US population, 
mostly among older adults [19]. Also, vilazodone was released in the US before being marketed 
in Asia and Europe. This might have accounted for the data been skewed to the US. 
The main objective of all the included studies were completed to evaluate the safety and 
efficacy of vilazodone for either the treatment of Major Depressive Disorder (MDD) or 
Generalized Anxiety Disorder (GAD). MDD is a serious, chronic and debilitating psychiatric 
illness affecting approximately 120 million individuals worldwide with a lifetime prevalence 
of 10-15% [20]. GAD is a condition of excessive and persistent worry about events in the 
future, with a distorted perception of risks and threats by patients [21]. GAD is associated with 
psychological symptoms including restlessness, difficulty concentrating, and disturbed sleep, 
often occurring comorbidly with MDD [22]. The recommended dose for vilazodone is 20–40 
mg/day [23], starting at 10mg per day titrated upward to a target dose of 40mg per day which 
is the dose level being evaluated for the treatment of GAD and MDD.  
In terms of patient demographics, vilazodone was mainly used by adult (18 – 70 years) female 
patients. The mean age for all included studies was 38 years. Vilazodone is an antidepressant 
mostly used by adult patients and rarely used in children below the age of 12 [4]. The use of 
antidepressants in adults has increased due to several factors, including an increase in the adult 
population on antidepressants therapies, duration of therapy, which is mostly 180days, and 
increase multiple chronic conditions within the adult population [19]. According to a recent 
study, it was found that 50% of antidepressants were prescribed for unapproved indications 
including chronic pain, tiredness, and sleep disturbance, which are also more common in older 
adults [19]. Due to the higher rate of use, most adverse events would be observed in adults.  
The mean percentage for the race group, which accounted for the highest population of users 
were white (76%). Nationally, it was found that black Americans with depressive or anxiety 
disorders were one-third less likely as white Americans to have used antidepressants, making 
the psychiatric need for antidepressants to be associated more with whites [24]. The mean 
percentage of users in this study were highest for females (65%), followed by males (35%). 
According to a study, females were about twice as likely as males to take antidepressant 
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medication [25]. Women are more likely to experience specific forms of depression-related 
illnesses, including postpartum depression, postmenopausal depression, and anxiety [26]. 
Female hormonal fluctuations may be a trigger for depression, making young women a higher 
risk for major depression and mental disorders globally [26].  
In patients with depression, synaptic levels of serotonin are regulated by 5-HT1A auto-
receptors. The activation of 5-HT1A auto-receptors, through the binding of serotonin, initially 
produces an increase of serotonin reuptake, thereby more of the neurotransmitter is available 
to interact with these receptors [27]. Current theory predicts that sustained, long-term 5-
HT1A receptor stimulation by vilazodone leads to a down-regulation of the auto-receptors so 
that, over time, serotonin release is no longer inhibited thereby causing psychiatric adverse 
effects, resulting in altered mentation and instability [28]. Since some drugs take a shorter time 
to relapse after discontinuation than expected, the combination of long-term drug treatment 
followed by withdrawal of vilazodone may be a causal factor in depression recurrence [29].  
A recent study also suggests that brain metabolism is reduced in the anterior cingulate which 
is responsible for emotional expression, in patients that suffer from depression. Therefore, 
leading to psychiatric adverse effects such as emotional blunting, numbing and mental status 
changes [30]. Kapur et al. proposed that prolonged and excessive serotonin in the synapse leads 
to a decrease in transmission of dopamine in the frontal lobe, causing a frontal lobe dysfunction, 
which is responsible for the apathy and emotional changes seen in patients [31]. 
Discontinuation reactions have been reported after withdrawal of prolonged vilazodone 
treatment. According to studies by Durgam et al., Khan et al., and Croft et al., adverse effects 
such as nightmares, suicidal ideation, depression, anxiety and abnormal dreams were all seen 
to have a higher incidence rate with the discontinuation of vilazodone than in comparison to 
the placebo drug used in respective studies. Insomnia, nightmares, anxiety, agitation, 
depressive mood, sudden crying, increased suicidal thoughts and confusion are psychiatric 
adverse effects most frequently associated with the discontinuation of an antidepressant [6]. 
Clinical trials show that this discontinuation syndrome results from neurophysiologic 
readjustment in the central nervous system which may be one of the main reasons for adverse 
effects caused by vilazodone [32]. Intolerability to medication is one of the most common 
reasons patients discontinue antidepressant treatment [33]. Patients should be monitored for 
these symptoms vilazodone dose should be tapered gradually when patients are discontinuing 
therapy [7].  
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In the analysis of Internet postings of users’ reviews of vilazodone according to the study by 
Hughes et al., it was seen that a greater range of behavioural and psychiatric adverse effects 
from users’ online postings appeared in comparison to published clinical trials [9]. Vilazodone 
users reported the highest rates of abnormal dreams, aggression and anger, aggravated 
depression and crying, sleep paralysis, agitation, and confusion in comparison to the other 
antidepressants. Psychiatric adverse effects in this study were more often reported over the 
initial weeks of vilazodone use. In this study, there were also meaningful differences in adverse 
effects among older and newer antidepressant agents. The more recently marketed drugs, such 
as vilazodone, had higher reports of aggressive behaviour, agitation, aggravated depression, 
and abnormal dreams. These effects contribute to emotional instability and are associated with 
increased suicidality [34]. The findings imply that important differences between 
antidepressants might be missed, due to poor adverse effect assessment in drug research [9]. 
The most important safety issue concerning depression is the reported link between suicidality 
and antidepressants. Antidepressants increase the risk of suicidal thinking and behaviour in 
adolescents, and adults with MDD and other psychiatric disorders [7]. In a study, SSRI use was 
associated with a nearly five-fold higher risk of completed suicide and suicidal thoughts in 
comparison to other antidepressants [35]. Antidepressant therapy involves a substantial delay 
before clinical improvements can occur, causing suicidal impulses. The 
psychopharmacological effects of SSRIs suggest that patients experience a worsening of mood 
with SSRI treatment and may cause agitation and impulsivity, resulting in an increased risk of 
suicide [35].  
The Columbia-Suicide Severity Rating Scale (C-SSRS) measures suicidal ideation and 
behaviour and gauges the severity over specified periods. This measure is considered essential 
in depressive patients for assessing suicide-related phenomena [36]. According to the C-SSRS 
findings in all pooled studies, the rates of suicidal ideation was more common in placebo treated 
patients than in vilazodone-treated patients in the included studies. Despite this, the rates of 
suicidal ideation and behaviour in some studies were still relatively high with the use of 
vilazodone. Although clinical trial reports usually provide suicide-related results, such 
information may be limited as suicidal events are uncommon and most trials specifically 
exclude patients with a current risk of suicide. A higher risk of suicidal ideation should 
encourage clinicians to be more cautious in their management, with intensive monitoring 
during the early phase of treatment [36].  
67 
 
While cardiac (e.g., dizziness) and gastrointestinal (e.g., nausea, vomiting) effects have been 
cited in published clinical trial research as adverse effects most often leading to treatment 
discontinuation [37], this analysis and review suggest that psychiatric effects might have a  
more significant role in treatment decision-making than previously recognized.  
LIMITATIONS AND RECOMMENDATIONS 
This systematic review was limited in its selection of databases and its restriction to English 
publications. Although an extensive review was covered, not all the literature obtained was 
relevant. This resulted in very small sample size and may not be representative of all the 
available research between January 2000 and January 2020. Also due to the heterogeneity in 
the data, it was not possible to undertake a meta‐ analytical approach. Vilazodone was only 
approved by the FDA and put onto the market in 2011, thus a considerably new drug with 
limited research. There are very few articles published that discuss the psychiatric adverse 
effects caused by vilazodone, which is why there is a need for post-marketing surveillance. 
Recommendations for future research will include an increase in studies conducted specifically 
on the psychiatric adverse effects caused by vilazodone.  
CONCLUSION 
The findings of this systematic review hypothesize that vilazodone has a greater range of 
psychiatric adverse effects than appears in published clinical trials. The analysis of reviews of 
vilazodone provides information about critical adverse effects yet to emerge in testing and 
surveillance. The present findings thus imply that significant adverse effects might be missed, 
due to the long-standing problem of poor assessment in drug research. 
Emotional and behavioural effects of antidepressants should be central to the process of 
monitoring and evaluating treatment benefits and harms. The most commonly used checklists 
in short-term clinical studies neglect psychiatric adverse effects, resulting in incomplete 
information about expected benefits and harms of the drug to patients and health care 
professionals. More intensive monitoring for psychiatric adverse effects may be appropriate 
for any user initiating vilazodone, and more considerable attention in research should be given 
to a broader range of effects that could affect treatment. Health care professionals should adopt 
tools to regularly monitor psychiatric adverse effects upon the initiation and withdrawal of 
vilazodone. Patients should be warned that vilazodone may induce altered emotions and 
prescribers should also be more aware of its’ mental effects to help make prescribing decisions 
more rational and effective.  
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Although vilazodone has proven efficacy in treating MDD and is being investigated for other 
possible indications, further detailed clinical trials are required to establish their psychiatric 
safety profile. Future research should more specifically and systematically examine these 
psychiatric adverse effects as they come into the market. 
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CHAPTER 5 
CONCLUSION 
Introduction   
This chapter highlights the significant findings of the study; it gives a general conclusion drawn 
from the study, states the strengths and limitations and provides recommendations for future 
studies.   
Vilazodone has several adverse effects, as listed in the PIL and known at the time of registration 
of the drug. However, being a relatively new drug, it is not clear if all adverse effects have been 
identified. It is therefore important to monitor for new or unknown adverse effects to improve 
and ensure the safety profile of the drug. This study was carried out to review the adverse 
effects of vilazodone using data of adverse events recorded on the PIDM site, VigiAccess. The 
study then went on to explore, in more detail the psychiatric adverse effects associated with 
vilazodone via a systematic review.   
In order to achieve this, the following specific objectives were outlined: 
 To identify and quantify the adverse effects associated with vilazodone reported in 
VigiAccess, according to organ systems. 
 To compare the adverse effects reported in VigiAccess to the adverse effects indicated 
during the FDA approval process. 
 To compare the adverse effects reported in VigiAccess to adverse effects indicated on 
the patient information leaflet for Viibryd®. 
 To describe the psychiatric adverse effects associated with the use of vilazodone. 
 
Conclusions drawn from the study findings based on each of the objectives    
At the time of the data extraction, a total of 9708 adverse events had been recorded on 
VigiAccess of which 6054 of these adverse events were not listed on the patient information 
leaflet (PIL) of Viibryd® and FDA approval document. The highest percentage of adverse 
events not recorded in the PIL or FDA but reported in VigiAccess were for psychiatric 
disorders (19%; n=1181). This included anxiety (26%; n=316), depression (17%; n=208), 
hallucinations (14%; n=168) and agitation (12%, n=142).  
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Upon further exploration of psychiatric adverse effects associated with vilazodone, abnormal 
dreams, agitation, aggression or increased anger, aggravated depression, crying, anxiety, 
confusion, depersonalization, emotional numbing, sleep paralysis, suicidal ideation or attempt, 
irritability and mental status changes were found to be associated with the drug. Of these, the 
adverse drug reactions with the highest occurrence included abnormal dreams, depression and 
suicidal ideation.  
Significance of the study 
 
The study of the safety profile of any drug is a significant part of pharmacovigilance. 
Monitoring of the drug post-marketing is necessary as the safety of a drug may evolve over 
time as it is used by different populations. This study found several adverse drug reactions only 
being observed after clinical trials.  More than half of the psychiatric adverse effects recorded 
on VigiAccess were not indicated on the PIL and FDA approval documentation, clearly 
indicating the need for continued monitoring of the safety aspects post-marketing. Post-
marketing surveillance provides valuable information on the use of drugs in special patient 
populations as well as allows for the long-term monitoring of the effects of drugs. As a 
relatively new drug, it is important to monitor vilazodone’s adverse effects in order to improve 
and ensure the safe prescribing of the drug.  
Strengths 
This study addresses a gap in the current knowledge by providing a comprehensive assessment 
of the psychiatric adverse effects which may influence the safe use of vilazodone as an 
antidepressant. The findings of this study can aid prescribers and other healthcare professionals 
to be aware of certain risks associated with the drug.  
Data collection for this study was cost-effective as the data sets used in the study were obtained 
from research articles and the free database VigiAccess.  
Limitations  
This study was limited in its selection of databases and its restriction to English publications 
as this may cause a language bias. Differences among the study designs and sample 
characteristics restricted comparison of selected studies. Although an extensive review was 
covered, not all the literature obtained was relevant. Vilazodone was only approved by the FDA 
and put onto the market in 2011, therefore, not many clinical trials have been able to study its 
long-term efficacy and adverse effects. At present, there are very few articles published that 
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discuss the psychiatric adverse effects caused by vilazodone, that is why there is a need for 
post-marketing surveillance. 
Recommendations 
Prescribers and other healthcare professionals should take cognisance of psychiatric adverse 
effects associated with vilazodone that could affect treatment.  This study highlights the need 
for continuous post-marketing surveillance of all, and specifically newer medicines. Continued 
surveillance improves the proper and safe use of medicines.  
Chapter summary 
The final chapter highlighted the conclusions drawn from the findings of the study, described 
the strengths and limitations of the study, as well as provided further recommendations. 
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School Of Health Sciences 
Westville 
 
 
 
Dear Dr Frasia Oosthuizen, 
 
Protocol reference number: 00002022 
Project title: Evaluating safety profiles of medication making use of VigiAccess 
 
Exemption from Ethics Review 
In response to your application received on 5 June 2019, your school has indicated that the protocol has 
been granted EXEMPTION FROM ETHICS REVIEW. 
Any alteration/s to the exempted research protocol, e.g., Title of the Project, Location of the Study, Research 
Approach and Methods must be reviewed and approved through an amendment/modification prior to its 
implementation. The original exemption number must be cited. 
 
For any changes that could result in potential risk, an ethics application including the proposed amendments must be 
submitted to the relevant UKZN Research Ethics Committee. The original exemption number must be cited. 
In case you have further queries, please quote the above reference number. 
 
PLEASE NOTE: 
Research data should be securely stored in the discipline/department for a period of 5 years. 
I take this opportunity of wishing you everything of the best with your study. 
 
Yours sincerely, 
 
 
 
------------------------------------------------------------ 
Prof Pragashnie Govender 
Academic Leader Research 
School Of Health Sciences 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UKZN Research Ethics Office 
Westville Campus, Govan Mbeki Building 
Postal Address: Private Bag X54001, Durban 4000 
Website: http://research.ukzn.ac.za/Research-Ethics/ 
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ANNEXURE: 3 
Submission guidelines for the Journal of Pharmacy Practice 
  
1. What do we publish? 
1.1 Aims & Scope 
Before submitting your manuscript to JPP, please ensure you have read the Aims & Scope. 
Journal of Pharmacy Practice is a peer-reviewed journal that offers practicing pharmacists in-depth 
useful reviews and research trials and surveys of new drugs and novel therapeutic approaches, 
pharmacotherapy reviews and controversies, pharmacokinetics, drug interactions, drug administration, 
adverse drug events, medication safety, pharmacy education, and other pharmacy practice topics 
1.2 Article types 
 Pharmacy Practice Review Articles 
a. Abstract (250-word limit) 
b. Keywords (5 keywords limit) 
c. References (100 limit) 
d. Word Count (5,000) 
  
 Drug or Therapeutic Review Articles 
a. Abstract (250-word limit) 
b. Keywords (5 keywords limit) 
c. References (150 limit) 
d. Word Count (5,000) 
  
 Continuing Education Articles 
a. Abstract (250-word limit) 
b. Keywords (5 keywords limit) 
c. Goals and objectives (7 limit) 
d. References (150 limit) 
e. Word Count (5,000) 
  
 Research Reports 
a. Structured Abstract (250-word limit) (to include Background, Objective, Methods, Results, 
Conclusion) 
b. Keywords (5 keywords limit) 
c. References (100 limit) 
d. Word Count (5,000) 
  
 Pharmacy Experiential Education 
a. Abstract (250-word limit) 
b. Keywords (5 keywords limit) 
c. References (100 limit) 
d. Word Count (4,000) 
  
 Adverse Drug Event Case Reports 
a. Abstract (250-word limit) 
b. Keywords (5 keywords limit) 
c. References (50 limit) 
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d. Word Count (2,500) 
  
 Case Reports or Case Studies 
a. Abstract (250-word limit) 
b. Keywords (5 keywords limit) 
c. References (50 limit) 
d. Word Count (2,500) 
  
 Biomedical Communications or Informatics Reviews 
a. No Abstract 
b. Keywords (5 keywords limit) 
c. References (10 limit) 
d. Word Count (1,500) 
  
 Editorial or Commentary 
a. Abstract (150-word limit) 
b. Keywords (5 keywords limit) 
c. References (20 limit) 
d. Word Count (1,500) 
  
 Letters to the Editor 
a. No Abstract 
b. Keywords (5 keywords limit) 
c. References (10 limit) 
d. Word Count (750) 
1.3 Writing your paper 
The SAGE Author Gateway has some general advice on how to get published, plus links to further 
resources. 
1.3.1 Make your article discoverable 
For information and guidance on how to make your article more discoverable, visit our Gateway page 
on How to Help Readers Find Your Article Online 
  
2. Editorial policies 
2.1 Peer review policy 
JPP adheres to a rigorous double-blind reviewing policy in which the identity of both the reviewer 
and author are always concealed from both parties. 
As part of the submission process you will be asked to provide the names of 2 peers who could be 
called upon to review your manuscript. Recommended reviewers should be experts in their fields and 
should be able to provide an objective assessment of the manuscript. Please be aware of any conflicts 
of interest when recommending reviewers. Examples of conflicts of interest include (but are not 
limited to) the below:  
 The reviewer should have no prior knowledge of your submission 
 The reviewer should not have recently collaborated with any of the authors 
 Reviewer nominees from the same institution as any of the authors are not permitted 
You will also be asked to nominate peers who you do not wish to review your manuscript (opposed 
reviewers). 
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Please note that the Editors are not obliged to invite/reject any recommended/opposed reviewers to 
assess your manuscript. 
JPP is committed to delivering high quality, fast peer-review for your paper, and as such has 
partnered with Publons. Publons is a third-party service that seeks to track, verify and give credit for 
peer review. Reviewers for the journal can opt in to Publons in order to claim their reviews or have 
them automatically verified and added to their reviewer profile. Reviewers claiming credit for their 
review will be associated with the relevant journal, but the article name, reviewer’s decision and the 
content of their review is not published on the site. For more information visit the Publons website. 
The Editor or members of the Editorial Board may occasionally submit their own manuscripts for 
possible publication in the journal. In these cases, the peer review process will be managed by 
alternative members of the Board and the submitting Editor/Board member will not be involved in the 
decision-making process. 
2.2 Authorship 
Papers should only be submitted for consideration once consent is given by all contributing authors. 
Those submitting papers should carefully check that all those whose work contributed to the paper are 
acknowledged as contributing authors. 
The list of authors should include all those who can legitimately claim authorship. This is all those 
who: 
1. Made a substantial contribution to the concept or design of the work; or acquisition, analysis 
or interpretation of data, 
2. Drafted the article or revised it critically for important intellectual content, 
3. Approved the version to be published, 
4. Each author should have participated sufficiently in the work to take public responsibility for 
appropriate portions of the content. 
Authors should meet the conditions of all the points above. When a large, multicentre group has 
conducted the work, the group should identify the individuals who accept direct responsibility for the 
manuscript. These individuals should fully meet the criteria for authorship. 
Acquisition of funding, collection of data, or general supervision of the research group alone does not 
constitute authorship, although all contributors who do not meet the criteria for authorship should be 
listed in the Acknowledgments section. Please refer to the International Committee of Medical 
Journal Editors (ICMJE) authorship guidelines for more information on authorship. 
2.3 Acknowledgements 
All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements 
section. Examples of those who might be acknowledged include a person who provided purely 
technical help, or a department chair who provided only general support. 
Please supply any personal acknowledgements separately to the main text to facilitate anonymous 
peer review. 
2.3.1 Writing assistance 
Individuals who provided writing assistance, e.g. from a specialist communications company, do not 
qualify as authors and so should be included in the Acknowledgements section. Authors must disclose 
any writing assistance – including the individual’s name, company and level of input – and identify 
the entity that paid for this assistance. It is not necessary to disclose use of language polishing 
services. 
2.4 Funding 
JPP requires all authors to acknowledge their funding in a consistent fashion under a separate 
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heading.  Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to 
confirm the format of the acknowledgment text in the event of funding, or state that: This research 
received no specific grant from any funding agency in the public, commercial, or not-for-profit 
sectors. 
2.5 Declaration of conflicting interests 
It is the policy of JPP to require a declaration of conflicting interests from all authors enabling a 
statement to be carried within the paginated pages of all published articles. 
Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your 
manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state 
that ‘The Author(s) declare(s) that there is no conflict of interest’. For guidance on conflict of interest 
statements, please see the ICMJE recommendations here 
2.6 Research ethics and patient consent 
Medical research involving human subjects must be conducted according to the World Medical 
Association Declaration of Helsinki 
Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, 
Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal 
and/or human studies must state in the methods section that the relevant Ethics Committee or 
Institutional Review Board provided (or waived) approval. Please ensure that you have provided the 
full name and institution of the review committee, in addition to the approval number. 
For research articles, authors are also required to state in the methods section whether participants 
provided informed consent and whether the consent was written or verbal. 
Information on informed consent to report individual cases or case series should be included in the 
manuscript text. A statement is required regarding whether written informed consent for patient 
information and images to be published was provided by the patient(s) or a legally authorized 
representative. Please do not submit the patient’s actual written informed consent with your article, as 
this in itself breaches the patient’s confidentiality. The Journal requests that you confirm to us, in 
writing, that you have obtained written informed consent but the written consent itself should be held 
by the authors/investigators themselves, for example in a patient’s hospital record. The confirmatory 
letter may be uploaded with your submission as a separate file. 
Please also refer to the ICMJE Recommendations for the Protection of Research Participants 
2.7 Clinical trials 
JPP conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public 
trials registry at or before the time of first patient enrolment as a condition of consideration for 
publication. The trial registry name and URL, and registration number must be included at the end of 
the abstract. 
2.8 Reporting guidelines 
The relevant EQUATOR Network reporting guidelines should be followed depending on the type of 
study. For example, all randomized controlled trials submitted for publication should include a 
completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be 
uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should 
include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist 
should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help 
you identify the appropriate guideline. 
Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives 
2.9. Research Data 
At SAGE we are committed to facilitating openness, transparency and reproducibility of research. 
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Where relevant, the journal encourages authors to share their research data in a suitable public 
repository subject to ethical considerations and where data is included, to add a data accessibility 
statement in their manuscript file. Authors should also follow data citation principles. For more 
information please visit the SAGE Author Gateway, which includes information about SAGE’s 
partnership with the data repository Figshare. 
  
3. Publishing policies 
3.1 Publication ethics 
SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer 
to the Committee on Publication Ethics’ International Standards for Authors and view the Publication 
Ethics page on the SAGE Author Gateway 
3.1.1 Plagiarism 
JPP and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in 
publication very seriously. We seek to protect the rights of our authors and we always investigate 
claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the 
journal against malpractice. Submitted articles may be checked with duplication-checking software. 
Where an article, for example, is found to have plagiarized other work or included third-party 
copyright material without permission or with insufficient acknowledgement, or where the authorship 
of the article is contested, we reserve the right to take action including, but not limited to: publishing 
an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of 
department or dean of the author's institution and/or relevant academic bodies or societies; or taking 
appropriate legal action. 
3.1.2 Prior publication 
If material has been previously published it is not generally acceptable for publication in a SAGE 
journal. However, there are certain circumstances where previously published material can be 
considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in doubt, 
contact the Editor at the address given below. 
3.2 Contributor’s publishing agreement       
Before publication, SAGE requires the author as the rights holder to sign a Journal Contributor’s 
Publishing Agreement. SAGE’s Journal Contributor’s Publishing Agreement is an exclusive licence 
agreement which means that the author retains copyright in the work but grants SAGE the sole and 
exclusive right and licence to publish for the full legal term of copyright. Exceptions may exist where 
an assignment of copyright is required or preferred by a proprietor other than SAGE. In this case 
copyright in the work will be assigned from the author to the society. For more information please 
visit the SAGE Author Gateway 
3.3 Open access and author archiving 
JPP offers optional open access publishing via the SAGE Choice programme. For more information 
please visit the SAGE Choice website. For information on funding body compliance, and depositing 
your article in repositories, please visit SAGE Publishing Policies on our Journal Author Gateway. 
  
4. Preparing your manuscript for submission 
4.1 Formatting 
The preferred format for your manuscript is Word. LaTeX files are also accepted. Word and (La)Tex 
templates are available on the Manuscript Submission Guidelines page of our Author Gateway. 
  
4.2 Artwork, figures and other graphics 
For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit 
SAGE’s Manuscript Submission Guidelines   
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Charges for color figures: $800.00 for the first figure and $200.00 for each additional figure. Color 
reproduction in the online PDF is free of charge. 
4.3 Supplemental material 
This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc.) 
alongside the full text of the article. For more information please refer to our guidelines on submitting 
supplemental files 
4.4 Reference style 
References must begin on a separate page. They must be numbered consecutively in the order in 
which they appear in the text by superscript Arabic numerals. References should be typed in the style 
adopted by the National Library of Medicine and used in Index Medicus with the exception that only 
the first 3 authors (last name and up to 2 initials) are listed. For example, a standard journal article 
with more than 3 authors should be listed as shown below. References should not include any 
unpublished observations or personal communications. 
1. Schoni MH, Casaulta-Aebischer C, Martinet LV, et al. Nutrition and lung function in cystic 
fibrosis patients: review. Clin Nutr. 2000; 19:79-85. 
4.5 English language editing services 
Authors seeking assistance with English language editing, translation, or figure and manuscript 
formatting to fit the journal’s specifications should consider using SAGE Language Services. 
Visit SAGE Language Services on our Journal Author Gateway for further information. 
5. Submitting your manuscript 
JPP is hosted on SAGE Track, a web based online submission and peer review system powered by 
ScholarOne™ Manuscripts. Visit https://mc.manuscriptcentral.com/jpp to login and submit your 
article online. 
IMPORTANT: Please check whether you already have an account in the system before trying to 
create a new one. If you have reviewed or authored for the journal in the past year it is likely that you 
will have had an account created.  For further guidance on submitting your manuscript online please 
visit ScholarOne Online Help. 
5.1 ORCID 
As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a 
supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a unique 
and persistent digital identifier that distinguishes researchers from every other researcher, even those 
who share the same name, and, through integration in key research workflows such as manuscript and 
grant submission, supports automated linkages between researchers and their professional activities, 
ensuring that their work is recognized. 
The collection of ORCID IDs from corresponding authors is now part of the submission process of 
this journal. If you already have an ORCID ID you will be asked to associate that to your submission 
during the online submission process. We also strongly encourage all co-authors to link their ORCID 
ID to their accounts in our online peer review platforms. It takes seconds to do: click the link when 
prompted, sign into your ORCID account and our systems are automatically updated. Your ORCID 
ID will become part of your accepted publication’s metadata, making your work attributable to you 
and only you. Your ORCID ID is published with your article so that fellow researchers reading your 
work can link to your ORCID profile and from there link to your other publications. 
If you do not already have an ORCID ID please follow this link to create one or visit our ORCID 
homepage to learn more. 
5.2 Information required for completing your submission 
You will be asked to provide contact details and academic affiliations for all co-authors via the 
submission system and identify who is to be the corresponding author. These details must match what 
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5.3 Permissions 
Please also ensure that you have obtained any necessary permission from copyright holders for 
reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. A 
permission form can be found at the end of these guidelines. For further information including 
guidance on fair dealing for criticism and review, please see the Copyright and Permissions page on 
the SAGE Author Gateway 
6. On acceptance and publication 
6.1 SAGE Production 
Your SAGE Production Editor will keep you informed as to your article’s progress throughout the 
production process. Proofs will be made available to the corresponding author via our editing portal 
SAGE Edit or by email, and corrections should be made directly or notified to us promptly. Authors 
are reminded to check their proofs carefully to confirm that all author information, including names, 
affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest 
statements, if any, are accurate. Please note that if there are any changes to the author list at this stage 
all authors will be required to complete and sign a form authorizing the change. 
6.2 Online First publication 
Online First allows final articles (completed and approved articles awaiting assignment to a future 
issue) to be published online prior to their inclusion in a journal issue, which significantly reduces the 
lead time between submission and publication. Visit the SAGE Journals help page for more details, 
including how to cite Online First articles. 
6.3 Access to your published article 
SAGE provides authors with online access to their final article. 
6.4 Promoting your article 
Publication is not the end of the process! You can help disseminate your paper and ensure it is as 
widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you 
promote your work. Visit the Promote Your Article page on the Gateway for tips and advice. 
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ANNEXURE: 6 
Submission guidelines for BMC Public Health 
 
Preparing your manuscript 
The information below details the section headings that you should include in your 
manuscript and what information should be within each section. 
Please note that your manuscript must include a 'Declarations' section including all of the 
subheadings (please see below for more information). 
Title page 
The title page should: 
 present a title that includes, if appropriate, the study design e.g.: 
o "A versus B in the treatment of C: a randomized controlled trial", "X is a risk 
factor for Y: a case control study", "What is the impact of factor X on subject 
Y: A systematic review" 
o or for non-clinical or non-research studies: a description of what the article 
reports 
 list the full names and institutional addresses for all authors 
o if a collaboration group should be listed as an author, please list the Group 
name as an author. If you would like the names of the individual members of 
the Group to be searchable through their individual PubMed records, please 
include this information in the “Acknowledgements” section in accordance 
with the instructions below 
 indicate the corresponding author 
Abstract 
The Abstract should not exceed 350 words. Please minimize the use of abbreviations and do 
not cite references in the abstract. 
Keywords 
Three to ten keywords representing the main content of the article. 
Background 
The Background section should explain the background to the article, its aims, a summary of 
a search of the existing literature and the issue under discussion. 
Main text 
This should contain the body of the article, and may also be broken into subsections with 
short, informative headings. 
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Conclusions 
This should state clearly the main conclusions and include an explanation of their relevance 
or importance to the field. 
List of abbreviations 
If abbreviations are used in the text they should be defined in the text at first use, and a list of 
abbreviations should be provided. 
Declarations 
All manuscripts must contain the following sections under the heading 'Declarations': 
 Ethics approval and consent to participate 
 Consent for publication 
 Availability of data and materials 
 Competing interests 
 Funding 
 Authors' contributions 
 Acknowledgements 
 Authors' information (optional) 
Please see below for details on the information to be included in these sections. 
If any of the sections are not relevant to your manuscript, please include the heading and 
write 'Not applicable' for that section.  
Ethics approval and consent to participate 
Manuscripts reporting studies involving human participants, human data or human tissue 
must: 
 include a statement on ethics approval and consent (even where the need for approval 
was waived) 
 include the name of the ethics committee that approved the study and the committee’s 
reference number if appropriate 
Studies involving animals must include a statement on ethics approval and for experimental 
studies involving client-owned animals, authors must also include a statement on informed 
consent from the client or owner. 
If your manuscript does not report on or involve the use of any animal or human data or 
tissue, please state “Not applicable” in this section. 
Consent for publication 
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If your manuscript contains any individual person’s data in any form (including any 
individual details, images or videos), consent for publication must be obtained from that 
person, or in the case of children, their parent or legal guardian. All presentations of case 
reports must have consent for publication. 
You can use your institutional consent form or our consent form if you prefer. You should 
not send the form to us on submission, but we may request to see a copy at any stage 
(including after publication). 
If your manuscript does not contain data from any individual person, please state “Not 
applicable” in this section. 
Availability of data and materials 
All manuscripts must include an ‘Availability of data and materials’ statement. Data 
availability statements should include information on where data supporting the results 
reported in the article can be found including, where applicable, hyperlinks to publicly 
archived datasets analysed or generated during the study. By data we mean the minimal 
dataset that would be necessary to interpret, replicate and build upon the findings reported in 
the article. We recognise it is not always possible to share research data publicly, for instance 
when individual privacy could be compromised, and in such instances data availability 
should still be stated in the manuscript along with any conditions for access. 
Data availability statements can take one of the following forms (or a combination of more 
than one if required for multiple datasets): 
 The datasets generated and/or analysed during the current study are available in the 
[NAME] repository, [PERSISTENT WEB LINK TO DATASETS] 
 The datasets used and/or analysed during the current study are available from the 
corresponding author on reasonable request. 
 All data generated or analysed during this study are included in this published article 
[and its supplementary information files]. 
 The datasets generated and/or analysed during the current study are not publicly 
available due [REASON WHY DATA ARE NOT PUBLIC] but are available from 
the corresponding author on reasonable request. 
 Data sharing is not applicable to this article as no datasets were generated or analysed 
during the current study. 
 The data that support the findings of this study are available from [third party name] 
but restrictions apply to the availability of these data, which were used under license 
for the current study, and so are not publicly available. Data are however available 
from the authors upon reasonable request and with permission of [third party name]. 
 Not applicable. If your manuscript does not contain any data, please state 'Not 
applicable' in this section. 
More examples of template data availability statements, which include examples of openly 
available and restricted access datasets, are available here. 
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BioMed Central also requires that authors cite any publicly available data on which the 
conclusions of the paper rely in the manuscript. Data citations should include a persistent 
identifier (such as a DOI) and should ideally be included in the reference list. Citations of 
datasets, when they appear in the reference list, should include the minimum information 
recommended by DataCite and follow journal style. Dataset identifiers including DOIs 
should be expressed as full URLs. For example: 
Hao Z, AghaKouchak A, Nakhjiri N, Farahmand A. Global integrated drought monitoring 
and prediction system (GIDMaPS) data sets. figshare. 
2014. http://dx.doi.org/10.6084/m9.figshare.853801 
With the corresponding text in the Availability of data and materials statement: 
The datasets generated during and/or analysed during the current study are available in the 
[NAME] repository, [PERSISTENT WEB LINK TO DATASETS].[Reference number]  
If you wish to co-submit a data note describing your data to be published in BMC Research 
Notes, you can do so by visiting our submission portal. Data notes support open data and help 
authors to comply with funder policies on data sharing. Co-published data notes will be 
linked to the research article the data support (example). 
Competing interests 
All financial and non-financial competing interests must be declared in this section. 
See our editorial policies for a full explanation of competing interests. If you are unsure 
whether you or any of your co-authors have a competing interest please contact the editorial 
office. 
Please use the authors initials to refer to each authors' competing interests in this section. 
If you do not have any competing interests, please state "The authors declare that they have 
no competing interests" in this section. 
Funding 
All sources of funding for the research reported should be declared. The role of the funding 
body in the design of the study and collection, analysis, and interpretation of data and in 
writing the manuscript should be declared. 
Authors' contributions 
The individual contributions of authors to the manuscript should be specified in this section. 
Guidance and criteria for authorship can be found in our editorial policies. 
Please use initials to refer to each author's contribution in this section, for example: "FC 
analyzed and interpreted the patient data regarding the hematological disease and the 
transplant. RH performed the histological examination of the kidney, and was a major 
contributor in writing the manuscript. All authors read and approved the final manuscript." 
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APPENDICES 
APPENDIX: 1 
NEW ADVERSE DRUG REACTIONS OF VILAZODONE NOT PRESENT IN THE FDA 
AND PIL 
BODY SYSTEM  
Blood and lymphatic system disorders Number of incidences reported (17) 
Anaemia 6 
Lymphadenopathy  6 
Blood disorder  1 
Increased tendency to bruise  1 
Splenic vein thrombosis  1 
Splenomegaly  1 
Thrombocytopenia  1 
Number of previously unreported ADRs – 7 
Most common unreported ADR’s- Anaemia and Lymphadenopathy 
Cardiac disorders Number of incidences reported (168) 
Palpitations # 115 
Tachycardia  16 
Atrial fibrillation  7 
Myocardial infarction  7 
Ventricular extrasystoles # 5 
Arrhythmia 4 
Cardiac disorder 4 
Supraventricular tachycardia 4 
Cardio-respiratory arrest 3 
Angina pectoris 2 
Atrial flutter 2 
Cardiac failure congestive 2 
Atrioventricular block 1 
Cardiac arrest 1 
Cardiac discomfort 1 
Cardiomegaly 1 
Cor pulmonale 1 
Coronary artery occlusion 1 
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Number of previously unreported ADRs – 24 
Most common unreported ADR’s- Tachycardia 
Ear and labyrinth disorders Number of incidences reported (84) 
Tinnitus  48 
Vertigo 25 
Ear discomfort 4 
Auditory disorder 2 
Deafness 2 
Ear pain 1 
Hyperacusis 1 
Hypoacusis 1 
Meniere's disease 1 
Number of previously unreported ADRs – 9 
Most common unreported ADR’s- Tinnitus and Vertigo 
 
Endocrine disorders Number of incidences reported (8) 
Hyperthyroidism  2 
Inappropriate antidiuretic hormone secretion 2 
Adrenocortical insufficiency acute 1 
Autoimmune thyroiditis 1 
Hyperprolactinaemia 1 
Hypothyroidism 1 
Number previously unreported ADRs – 6 
Most common unreported ADR’s- Hyperthyroidism  
Cyanosis 1 
Extrasystoles 1 
Foetal heart rate deceleration abnormality  1 
Long QT syndrome 1 
Sinus bradycardia 1 
Stress cardiomyopathy 1 
Supraventricular extrasystoles 1 
Wolff-Parkinson-White syndrome 1 
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Eye disorders Number of incidences reported (164) 
Vision blurred  69 
Visual impairment  19 
Dry eye  13 
Eye swelling 9 
Lacrimation increased 8 
Eye pain  7 
Ocular hyperaemia  7 
Eye pruritus 6 
Asthenopia 5 
Blindness transient  5 
Eye movement disorder 5 
Mydriasis 5 
Abnormal sensation in eye 4 
Blepharospasm 4 
Eye irritation 4 
Photopsia 4 
Eye disorder 3 
Photophobia 3 
Visual acuity reduced 3 
Cataract 2 
Diplopia 2 
Dyschromatopsia 2 
Eyelid oedema 2 
Ocular discomfort 2 
Vitreous detachment 2 
Altered visual depth perception 1 
Angle closure glaucoma 1 
Blepharitis 1 
Blindness 1 
Blindness unilateral 1 
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Chromatopsia 1 
Conjunctival haemorrhage 1 
Contact lens intolerance 1 
Dark circles under eyes 1 
Episcleritis 1 
Exophthalmos 1 
Eye discharge 1 
Foreign body sensation in eyes 1 
Halo vision 1 
Lid sulcus deepened 1 
Miosis 1 
Night blindness 1 
Periorbital oedema 1 
Strabismus 1 
Swelling of eyelid 1 
Visual brightness 1 
Vitreous floaters 1 
Number of previously unreported ADRs – 47 
Most common unreported ADR’s- Vision blurred  
 
Gastrointestinal disorders Number of incidences reported (1839) 
Diarrhoea #* 582 
Nausea #* 477 
Vomiting #*  140 
Abdominal pain upper # 75 
Abdominal discomfort # 74 
Abdominal pain # 47 
Dry mouth # 47 
Abdominal distension # 38 
Flatulence  33 
Dyspepsia  28 
Constipation  26 
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Gastrointestinal disorder  20 
Gastrooesophageal reflux disease  17 
Haematochezia  11 
Rectal haemorrhage  11 
Frequent bowel movements  10 
Swollen tongue  10 
Pancreatitis  8 
Gastritis  7 
Lip swelling  6 
Anal incontinence  5 
Irritable bowel syndrome  5 
Stomatitis  5 
Tongue disorder  5 
Diarrhoea haemorrhagic  4 
Eructation  4 
Gastric disorder  4 
Gastrointestinal sounds abnormal  4 
Haemorrhoids 4 
Hypoaesthesia oral  4 
Pancreatitis acute  4 
Abdominal pain lower  3 
Haematemesis  3 
Retching  3 
Abnormal faeces  2 
Colitis  2 
Defaecation urgency  2 
Dysphagia  2 
Faeces discoloured  2 
Gastrointestinal haemorrhage  2 
Malabsorption  2 
Oedema mouth  2 
Oral disorder  2 
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Paraesthesia oral  2 
Proctitis ulcerative  2 
Salivary hypersecretion  2 
Tooth loss  2 
Toothache  2 
Anal sphincter atony  1 
Anorectal disorder  1 
Aptyalism  1 
Change of bowel habit  1 
Coating in mouth  1 
Colitis ulcerative  1 
Crohn's disease  1 
Dental discomfort  1 
Duodenitis  1 
Epigastric discomfort  1 
Erosive duodenitis  1 
Faeces soft  1 
Food poisoning  1 
Gastric ulcer  1 
Gastrointestinal hypomotility  1 
Gastrointestinal motility disorder  1 
Gastrointestinal pain  1 
Gastrointestinal tract irritation  1 
Gingival bleeding  1 
Gingival pain  1 
Glossodynia  1 
Hiatus hernia 1 
Impaired gastric emptying  1 
Inflammatory bowel disease  1 
Infrequent bowel movements  1 
Lip disorder  1 
Lip exfoliation  1 
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Lip pain  1 
Lip ulceration  1 
Melaena  1 
Mouth ulceration  1 
Mucous stools  1 
Noninfective gingivitis  1 
Oesophagitis  1 
Oral discomfort  1 
Oral mucosal eruption  1 
Pancreatic pseudocyst  1 
Peptic ulcer  1 
Plicated tongue  1 
Small intestinal haemorrhage  1 
Tongue oedema  1 
Tongue spasm  1 
Tooth deposit  1 
Tooth discolouration 1 
Aptyalism  1 
Change of bowel habit  1 
Coating in mouth  1 
Colitis ulcerative  1 
Crohn's disease  1 
Dental discomfort  1 
Duodenitis  1 
Epigastric discomfort  1 
Erosive duodenitis  1 
Faeces soft  1 
Food poisoning  1 
Gastric ulcer  1 
Gastrointestinal hypomotility  1 
Gastrointestinal motility disorder  1 
Gastrointestinal pain  1 
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Gastrointestinal tract irritation  1 
Gingival bleeding  1 
Gingival pain  1 
Glossodynia  1 
Hiatus hernia  1 
Impaired gastric emptying  1 
Inflammatory bowel disease  1 
Infrequent bowel movements  1 
Lip disorder  1 
Lip exfoliation  1 
Lip pain  1 
Lip ulceration  1 
Melaena  1 
Mouth ulceration  1 
Mucous stools 1 
Noninfective gingivitis  1 
Oesophagitis  1 
Oral discomfort  1 
Oral mucosal eruption  1 
Pancreatic pseudocyst  1 
Peptic ulcer  1 
Plicated tongue  1 
Small intestinal haemorrhage 1 
Tongue oedema  1 
Tongue spasm  1 
Tooth deposit  1 
Tooth discolouration  1 
Vomiting projectile  1 
Number of previously unreported ADR’s- 359 
Most common unreported ADR’s- Flatulence and Dyspepsia 
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General disorders and administration site 
conditions 
Number of incidences reported 
(1134) 
Feeling abnormal  239 
Drug ineffective  199 
Fatigue # 157 
Crying  102 
Asthenia  72 
Malaise  71 
Feeling jittery  53 
Pain  52 
Unevaluable event  42 
Drug interaction  37 
Gait disturbance  33 
Chest pain  32 
Withdrawal syndrome  32 
Condition aggravated  26 
Oedema peripheral  26 
Chest discomfort  24 
Pyrexia  24 
Death  21 
Feeling hot  21 
Drug withdrawal syndrome  20 
Influenza like illness  19 
Chills  18 
Therapeutic response unexpected  18 
Energy increased  14 
Oedema  13 
Screaming  12 
Therapeutic product effect increased  12 
Feeling cold  10 
Swelling  10 
Therapeutic product effect decreased  10 
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Adverse event  9 
Therapeutic response decreased  8 
Adverse drug reaction  7 
Peripheral swelling  7 
Sluggishness  7 
Discomfort  6 
Drug intolerance 6 
Gait inability 6 
Drug ineffective for unapproved indication  5 
No adverse event  5 
Feeling drunk  4 
Hunger  4 
Thirst  4 
Inflammation  3 
Nonspecific reaction  3 
Temperature intolerance  3 
Therapeutic product effect incomplete  3 
Therapy non-responder  3 
Adverse reaction  2 
Disease recurrence  2 
Face oedema  2 
Hangover  2 
Ill-defined disorder  2 
Mucosal dryness  2 
Potentiating drug interaction  2 
Pre-existing condition improved  2 
Apparent death  1 
Axillary pain  1 
Chronic disease  1 
Cyst  1 
Drug resistance  1 
Exercise tolerance decreased  1 
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Hepatobiliary disorders Number of incidences reported 
(17) 
Hepatitis  3 
Gallbladder disorder  2 
Jaundice  2 
Liver disorder  2 
Acute hepatic failure  1 
Autoimmune hepatitis  1 
Cholecystitis  1 
Cholecystitis acute  1 
Cholelithiasis  1 
Drug-induced liver injury  1 
Hepatic failure  1 
Hepatic steatosis  1 
Impaired self-care  1 
Inflammatory pain  1 
Injection site pain  1 
Localised oedema  1 
Loss of control of legs  1 
Multiple organ dysfunction syndrome  1 
Polyp  1 
Secretion discharge  1 
Sensation of foreign body  1 
Therapeutic product effective for unapproved 
indication  
1 
Therapeutic response changed  1 
Thirst decreased 1 
Treatment noncompliance  1 
Ulcer  1 
Number of previously unreported ADR’s-977 
Most common unreported ADR’s- Feeling abnormal, ineffective drug and crying 
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Number of previously unreported ADR’s – 17 
Most common unreported ADR’s- Hepatitis 
Immune system disorders Number of incidences reported 
(56) 
Drug hypersensitivity  28 
Hypersensitivity  21 
Anaphylactic reaction 3 
Anaphylactic shock 2 
Allergy to plants  1 
Mycotic allergy  1 
Number of previously unreported ADR’s – 56 
Most common unreported ADR’s- Drug hypersensitivity 
Infections and infestations Number of incidences reported 
(60) 
Sinusitis  8 
Influenza  6 
Urinary tract infection 5 
Bronchitis  4 
Nasopharyngitis 4 
Pneumonia 4 
Herpes zoster  3 
Kidney infection  3 
Viral infection  3 
Vulvovaginal mycotic infection  3 
Cystitis  2 
Gastroenteritis  2 
Infection  2 
Abdominal abscess  1 
Abscess 1 
Abscess limb  1 
Ear infection  1 
Eye infection  1 
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Fungal infection  1 
Fungal skin infection 1 
Gastroenteritis viral  1 
Gingivitis  1 
Hepatitis B  1 
Herpes virus infection  1 
Mastitis  1 
Mastoiditis 1 
Oral candidiasis  1 
Oral herpes  1 
Pyuria  1 
Rash pustular 1 
Staphylococcal infection  1 
Streptococcal infection  1 
Subcutaneous abscess  1 
Tooth abscess  1 
Tooth infection  1 
Upper respiratory tract infection  1 
Urethritis  1 
Number of previously unreported ADR’s – 60 
Most common unreported ADR’s- Sinusitis and Influenza 
Injury, poisoning and procedural complications Number of incidences reported 
(862) 
Off label use  438 
Product dose omission  74 
Intentional product misuse  54 
Wrong technique in product usage process  51 
Contusion  39 
Fall  31 
Intentional overdose  30 
Overdose  24 
Expired product administered  22 
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Incorrect dose administered  19 
Medication error  18 
Inappropriate schedule of product administration  14 
Toxicity to various agents  14 
Product prescribing error  13 
Accidental overdose  12 
Product use issue  10 
Road traffic accident  10 
Accidental exposure to product  9 
Prescribed overdose 9 
Gun shot wound  6 
Head injury 6 
Intentional dose omission  6 
Drug titration error  5 
Accidental exposure to product by child  4 
Concussion  4 
Exposure during pregnancy  4 
Intentional product use issue  4 
Skin laceration  4 
Ankle fracture  3 
Joint injury  3 
Product dispensing error  3 
Scar 3 
Scratch  3 
Wrong product administered  3 
Accident  2 
Discontinued product administered 2 
Electric shock  2 
Incorrect dosage administered  2 
Ligament sprain  2 
Maternal exposure during breast feeding  2 
Product administration error  2 
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Product use in unapproved indication  2 
Rib fracture  2 
Sunburn  2 
Tooth fracture  2 
Arthropod bite  1 
Back injury 1 
Bite  1 
Chemical poisoning  1 
Contraindicated product administered  1 
Contraindicated product prescribed  1 
Corneal abrasion  1 
Craniocerebral injury  1 
Depression postoperative  1 
Drug dose titration not performed  1 
Extra dose administered  1 
Fibula fracture  1 
Foot fracture  1 
Heat exhaustion  1 
Hip fracture  1 
Hypobarism  1 
Incorrect product administration duration  1 
Incorrect route of product administration  1 
Injury  1 
Intercepted product prescribing error  1 
Labelled drug-drug interaction medication error  1 
Maternal exposure during pregnancy  1 
Multiple fractures  1 
Nerve injury  1 
Poisoning  1 
Procedural complication  1 
Product name confusion  1 
Product preparation error  1 
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Skin abrasion  1 
Skin wound  1 
Thermal burn  1 
Underdose  1 
Upper limb fracture  1 
Wrong patient received product  1 
Number of previously unreported ADR’s – 862 
Most common unreported ADR’s- Off label use and product dose omission  
Investigations Number of incidences reported 
(421) 
Weight increased # 141 
Blood pressure increased  66 
Heart rate increased  40 
Blood glucose increased  38 
Weight decreased  38 
Blood pressure decreased  9 
Blood glucose decreased  8 
Drug screen positive  8 
Heart rate irregular  7 
Hepatic enzyme increased  7 
Blood cholesterol increased  6 
Drug screen false positive  6 
Alanine aminotransferase increased  5 
Body temperature increased  5 
International normalised ratio increased 5 
Blood triglycerides increased  4 
Haemoglobin decreased  4 
Heart rate decreased  4 
Aspartate aminotransferase increased  3 
Blood creatine phosphokinase increased 3 
Blood creatinine increased  3 
Blood potassium decreased  3 
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Blood sodium decreased  3 
Electrocardiogram abnormal  3 
Glycosylated haemoglobin increased  3 
Platelet count decreased  3 
Blood glucose fluctuation  2 
Blood urea increased  2 
Blood urine present  2 
C-reactive protein increased  2 
Electrocardiogram QT prolonged  2 
Hepatic enzyme abnormal  2 
Liver function test abnormal  2 
Oxygen saturation decreased  2 
Prostatic specific antigen increased  2 
Respiratory rate increased  2 
Urine output decreased  2 
White blood cell count decreased 2 
Vitamin B12 decreased  2 
Vitamin D decreased  2 
Amphetamines positive  1 
Bleeding time prolonged  1 
Blood alkaline phosphatase abnormal  1 
Blood alkaline phosphatase increased 1 
Blood bilirubin abnormal  1 
Blood bilirubin increased  1 
Blood calcium abnormal  1 
Blood calcium decreased  1 
Blood chloride decreased  1 
Blood count abnormal  1 
Blood electrolytes decreased  1 
Blood iron decreased  1 
Blood magnesium  1 
Blood oestrogen increased  1 
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Blood potassium increased  1 
Blood pressure abnormal  1 
Blood pressure measurement  1 
Blood pressure systolic increased  1 
Blood testosterone increased  1 
Blood thyroid stimulating hormone decreased 1 
Body temperature abnormal 1 
Cortisol decreased  1 
CSF pressure increased  1 
Electrocardiogram 1 
Electrocardiogram change  1 
Electrocardiogram T wave amplitude decreased  1 
Glomerular filtration rate decreased  1 
Haematocrit increased  1 
Hepatic enzyme  1 
Intraocular pressure increased  1 
JC polyomavirus test positive  1 
Laboratory test abnormal  1 
Liver function test increased  1 
pH urine increased  1 
Pulse abnormal  1 
Quality of life decreased  1 
Red blood cell count decreased  1 
Red blood cell sedimentation rate increased 1 
Respiratory rate decreased  1 
Toxicologic test abnormal  1 
Ultrasound antenatal screen abnormal  1 
Urine amphetamine positive  1 
Number of previously unreported ADR’s – 421 
Most common unreported ADR’s- Blood pressure and heart rate increased 
Metabolism and nutrition disorders Number of incidences reported 
(157) 
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Decreased appetite # 58 
Increased appetite # 38 
Hyponatraemia  14 
Dehydration  9 
Food craving  6 
Fluid retention  4 
Hyperglycaemia  4 
Diabetes mellitus  3 
Hypokalaemia  3 
Hypophagia  3 
Appetite disorder  2 
Cardiometabolic syndrome  2 
Diabetes mellitus inadequate control  2 
Diabetic ketoacidosis  2 
Feeding disorder  2 
Hypoglycaemia  2 
Lactose intolerance  2 
Abnormal loss of weight  1 
Abnormal weight gain  1 
Fluid overload  1 
Glucose tolerance impaired  1 
Gout  1 
Hyperkalaemia  1 
Hyperphagia  1 
Malnutrition  1 
Metabolic acidosis  1 
Obesity 1 
Weight fluctuation  1 
Weight loss poor  1 
Vitamin D deficiency  1 
Number of previously unreported ADR’s – 61 
Most common unreported ADR’s- Hyponatremia  
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Musculoskeletal and connective tissue disorders Number of incidences reported 
(343) 
Muscle spasms  73 
Arthralgia # 64 
Muscle twitching  58 
Myalgia  50 
Pain in extremity  44 
Musculoskeletal stiffness  36 
Back pain  17 
Muscular weakness  15 
Joint swelling  14 
Muscle tightness  13 
Musculoskeletal pain 8 
Joint stiffness 7 
Neck pain 6 
Fibromyalgia  5 
Muscle rigidity  5 
Musculoskeletal discomfort  5 
Pain in jaw  5 
Arthritis  3 
Mobility decreased 3 
Tendon pain  3 
Extremity contracture  2 
Flank pain 2 
Intervertebral disc protrusion  2 
Joint noise  2 
Rhabdomyolysis  2 
Rheumatoid arthritis  2 
Spinal stenosis  2 
Arthritis enteropathic  1 
Arthropathy  1 
Bone disorder  1 
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Bone pain  1 
Finger deformity  1 
Foot deformity  1 
Groin pain  1 
Jaw disorder  1 
Joint range of motion decreased  1 
Limb discomfort 1 
Muscle atrophy  1 
Muscle disorder  1 
Muscle fatigue  1 
Musculoskeletal chest pain  1 
Musculoskeletal disorder  1 
Myositis  1 
Polyarthritis  1 
Scoliosis  1 
Spinal disorder  1 
Systemic lupus erythematosus  1 
Temporomandibular joint syndrome  1 
Tendonitis  1 
Number of previously unreported ADR’s-343 
Most common unreported ADR’s- Muscle twitching and muscle spasms 
 
Neoplasms benign, malignant and unspecified          
(incl cysts and polyps) 
Number of incidences reported 
(13) 
Neoplasm malignant  2 
Renal cancer  2 
Thyroid cancer  2 
Bladder cancer  1 
Breast cancer stage IV  1 
Hepatic neoplasm  1 
Juvenile melanoma benign  1 
Lung neoplasm malignant  1 
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Melanocytic naevus  1 
Neoplasm skin  1 
Number of previously unreported ADR’s – 13 
 
Nervous system disorders Number of incidences reported 
(1433) 
Dizziness # 298 
Headache # 288 
Paraesthesia #  246 
Tremor # 144 
Somnolence # 136 
Serotonin syndrome  82 
Seizure  72 
Amnesia  53 
Memory impairment  51 
Hypoaesthesia  48 
Sleep paralysis #* 47 
Loss of consciousness  44 
Migraine # 42 
Lethargy  38 
Disturbance in attention  35 
Restless legs syndrome  33 
Balance disorder  24 
Speech disorder  24 
Dyskinesia  23 
Syncope  21 
Generalised tonic-clonic seizure  18 
Burning sensation  17 
Dysgeusia  15 
Hypersomnia  13 
Movement disorder  13 
Psychomotor hyperactivity  13 
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Cognitive disorder  12 
Coordination abnormal  12 
Sensory disturbance  12 
Paralysis  11 
Dysarthria  10 
Mental impairment  10 
Sedation  10 
Ageusia 9 
Formication 8 
Head discomfort  8 
Poor quality sleep  8 
Aphasia 7 
Nervous system disorder 7 
Akathisia 6 
Cerebrovascular accident 6 
Anosmia  5 
Dystonia 5 
Hyperreflexia 5 
Cerebral disorder  4 
Cerebral haemorrhage  4 
Clumsiness  4 
Neuroleptic malignant syndrome  4 
Partial seizures  4 
Petit mal epilepsy  4 
Altered state of consciousness  3 
Dysstasia  3 
Encephalopathy  3 
Hypokinesia  3 
Judgement impaired 3 
Neuralgia 3 
Parkinsonism 3 
Parosmia 3 
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Presyncope 3 
Slow speech  3 
Tension headache 3 
Tunnel vision 3 
Aura 2 
Cerebral infarction 2 
Cold-stimulus headache  2 
Depressed level of consciousness 2 
Drooling  2 
Epilepsy  2 
Extrapyramidal disorder  2 
Facial paralysis  2 
Hyposmia  2 
Incoherent  2 
Motor dysfunction  2 
Muscle spasticity  2 
Myoclonus  2 
Parkinsonian rest tremor  2 
Seizure like phenomena  2 
Tardive dyskinesia  2 
Visual field defect  2 
Ataxia 1 
Brain injury  1 
Burning feet syndrome  1 
Carpal tunnel syndrome 1 
Cataplexy  1 
Chronic inflammatory demyelinating 
polyradiculoneuropathy  
1 
Clonus  1 
Coma  1 
Cranial nerve disorder  1 
Dementia  1 
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Dizziness postural  1 
Dreamy state  1 
Dysgraphia  1 
Epileptic aura  1 
Guillain-Barre syndrome  1 
Haemorrhage intracranial  1 
Head titubation  1 
Hemiparesis  1 
Hypertonia 1 
Hypogeusia  1 
Language disorder  1 
Migraine with aura  1 
Monoplegia  1 
Multiple sclerosis  1 
Muscle contractions involuntary  1 
Neuritis 1 
Neuropathy peripheral  1 
Nystagmus 1 
Olfactory nerve disorder  1 
Paraparesis  1 
Paraplegia  1 
Parkinson's disease  1 
Resting tremor  1 
Sciatica 1 
Sinus headache  1 
Slow response to stimuli  1 
Status epilepticus 1 
Stupor  1 
Subarachnoid haemorrhage  1 
Tongue biting  1 
Transient ischaemic attack  1 
Unresponsive to stimuli  1 
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Number of previously unreported ADR’s – 232 
Most common unreported ADR’s- Serotonin syndrome and Seizures 
Pregnancy, puerperium and perinatal 
conditions 
Number of incidences reported (5) 
Abortion spontaneous  2 
Foetal death  2 
Pregnancy  1 
Number of previously unreported ADR’s – 5 
Product issues Number of incidences reported (13) 
Product substitution issue  4 
Product quality issue  3 
Failure of child resistant mechanism for 
pharmaceutical product  
1 
Product formulation issue  1 
Product label issue  1 
Product lot number issue  1 
Product physical issue  1 
Product taste abnormal  1 
Number of previously unreported ADR’s – 13 
Psychiatric disorders Number of incidences reported 
(1889) 
Insomnia #* 455 
Anxiety  316 
Depression  208 
Suicidal ideation  205 
Hallucination  168 
Agitation  142 
Abnormal dreams #  126 
Nightmare  121 
Irritability  107 
Confusional state  96 
Panic attack # 85 
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Anger  77 
Mania 70 
Aggression  61 
Suicide attempt 57 
Nervousness 55 
Completed suicide  52 
Restlessness # 42 
Paranoia  39 
Disorientation  33 
Hallucination, auditory  33 
Sleep terror  31 
Hallucination, visual  29 
Abnormal behaviour  26 
Depressed mood  26 
Mood swings  26 
Psychotic disorder  24 
Thinking abnormal  24 
Sleep disorder  23 
Libido decreased  22 
Tachyphrenia  21 
Fear 19 
Mood altered  19 
Stress  19 
Emotional disorder  17 
Mental status changes  14 
Middle insomnia  13 
Hypomania  12 
Mental disorder  12 
Anorgasmia  11 
Apathy 11 
Intentional self-injury  10 
Tearfulness  10 
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Initial insomnia  9 
Bruxism 8 
Hallucinations, mixed  8 
Hypnagogic hallucination  8 
Impulsive behaviour  8 
Terminal insomnia 8 
Violence-related symptom  8 
Affect lability  7 
Decreased interest  7 
Delirium  7 
Euphoric mood  7 
Hostility 7 
Personality change  7 
Suicidal behaviour  7 
Emotional distress  6 
Logorrhoea  6 
Morbid thoughts  6 
Obsessive-compulsive disorder 6 
Somnambulism  6 
Affective disorder 5 
Drug dependence  5 
Loss of libido 5 
Panic reaction 5 
Bradyphrenia  4 
Delusion 4 
Dissociation 4 
Dysphemia  4 
Feeling of despair  4 
Homicidal ideation  4 
Libido increased  4 
Obsessive thoughts  4 
Panic disorder  4 
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Rapid eye movements sleep abnormal  4 
Tension 4 
Bipolar disorder  3 
Derealisation  3 
Impulse-control disorder  3 
Negative thoughts  3 
Social avoidant behaviour  3 
Tic  3 
Abnormal sleep-related event  2 
Anxiety disorder 2 
Communication disorder  2 
Confabulation 2 
Conversion disorder  2 
Daydreaming 2 
Dependence  2 
Disturbance in sexual arousal  2 
Eating disorder  2 
Fear of death  2 
Female orgasmic disorder  2 
Flashback   2 
Head banging  2 
Hypervigilance  2 
Impatience  2 
Listless  2 
Major depression  2 
Male orgasmic disorder  2 
Obsessive-compulsive symptom  2 
Orgasm abnormal  2 
Self esteem decreased 2 
Staring  2 
Acute stress disorder  1 
Agoraphobia  1 
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Alcoholism  1 
Arachnophobia  1 
Autoscopy  1 
Binge drinking  1 
Change in sustained attention  1 
Compulsive cheek biting  1 
Delusional disorder, unspecified type 1 
Depressive symptom  1 
Dermatillomania  1 
Disinhibition 1 
Dissociative amnesia  1 
Dissociative disorder  1 
Dysphoria  1 
Enuresis  1 
Excessive sexual fantasies  1 
Fear of disease  1 
Flat affect  1 
Frustration tolerance decreased  1 
Grandiosity  1 
Hallucination, gustatory  1 
Hallucination, tactile  1 
Helplessness  1 
Illusion  1 
Loss of dreaming  1 
Merycism  1 
Onychophagia  1 
Orgasmic sensation decreased  1 
Parasomnia  1 
Performance fear  1 
Phobia of driving  1 
Premature ejaculation  1 
Psychogenic seizure  1 
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Psychomotor retardation  1 
Psychotic behaviour  1 
Self-injurious ideation  1 
Sexually inappropriate behaviour  1 
Sleep talking  1 
Substance-induced psychotic disorder  1 
Number of previously unreported ADR’s – 1181 
Most common unreported ADR’s- Anxiety, Depression, Suicidal ideation, Hallucination 
and Agitation 
Renal and urinary disorders Number of incidences reported (70) 
Pollakiuria  14 
Urinary retention  7 
Dysuria 6 
Urinary hesitation  6 
Incontinence  5 
Urinary incontinence  5 
Acute kidney injury  2 
Bladder discomfort  2 
Bladder irritation  2 
Chromaturia  2 
Haematuria  2 
Nephrolithiasis  2 
Nocturia  2 
Renal disorder  2 
Renal failure  2 
Bladder spasm  1 
Glomerulonephritis  1 
Micturition disorder  1 
Micturition frequency decreased  1 
Micturition urgency  1 
Renal pain  1 
Urinary bladder haemorrhage  1 
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Urine flow decreased  1 
Urine odour abnormal  1 
Number of previously unreported ADR’s – 70 
Most common unreported ADR’s- Pollakiuria 
Reproductive system and breast disorders Number of incidences reported 
(125) 
Sexual dysfunction # 34 
Erectile dysfunction # 14 
Vaginal haemorrhage  10 
Priapism  6 
Menorrhagia  5 
Metrorrhagia  5 
Ejaculation failure # 4 
Menstruation irregular  4 
Breast tenderness  3 
Ejaculation delayed  2 
Menopausal symptoms  2 
Penile haemorrhage  2 
Polymenorrhoea  2 
Premenstrual syndrome  2 
Spontaneous penile erection  2 
Vulvovaginal dryness  2 
Amenorrhoea  1 
Breast atrophy  1 
Breast discharge  1 
Breast enlargement  1 
Breast swelling  1 
Dysmenorrhoea  1 
Ejaculation disorder  1 
Endometriosis  1 
Infertility  1 
Menometrorrhagia  1 
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Menstrual disorder  1 
Menstruation delayed  1 
Ovarian enlargement  1 
Ovulation disorder  1 
Pelvic pain  1 
Penile size reduced  1 
Penis disorder  1 
Peyronie's disease  1 
Prostatomegaly 1 
Semen discolouration  1 
Testicular pain  1 
Uterine pain  1 
Vaginal discharge 1 
Vulvovaginal burning sensation  1 
Vulvovaginal pain  1 
Number of previously unreported ADR’s – 73 
Respiratory, thoracic and mediastinal 
disorders 
Number of incidences reported 
(151) 
Dyspnoea  63 
Cough  15 
Pulmonary embolism  7 
Epistaxis  6 
Oropharyngeal pain  6 
Asthma  5 
Respiratory disorder  5 
Sleep apnoea syndrome  5 
Throat tightness  5 
Aspiration  4 
Dysphonia  4 
Nasal congestion  4 
Asphyxia  3 
Haemoptysis  3 
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Lung disorder  3 
Pharyngeal oedema 3 
Rhinorrhoea  3 
Sneezing 3 
Choking sensation  2 
Dry throat 2 
Hyperventilation 2 
Nasal pruritus  2 
Pulmonary hypertension  2 
Respiratory tract congestion  2 
Acute respiratory failure  1 
Apnoea  1 
Apparent life threatening event  1 
Bronchospasm  1 
Choking  1 
Dyspnoea exertional  1 
Hiccups  1 
Hypopnoea  1 
Hypoxia  1 
Laryngospasm  1 
Nasal dryness  1 
Oropharyngeal discomfort 1 
Pharyngeal disorder  1 
Pneumonia aspiration  1 
Productive cough  1 
Pulmonary mass  1 
Pulmonary oedema  1 
Reflux laryngitis  1 
Respiratory failure  1 
Sinus congestion  1 
Throat irritation  1 
Yawning  1 
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Number of previously unreported ADR’s – 151 
Most common unreported ADR’s- Dyspnoea 
Skin and subcutaneous tissue disorders Number of incidences reported 
(552) 
Hyperhidrosis # 96 
Pruritus  84 
Alopecia  68 
Rash  68 
Night sweats # 31 
Urticaria  25 
Pruritus generalised  19 
Swelling face  18 
Acne  15 
Cold sweat  11 
Erythema  9 
Rash pruritic  8 
Psoriasis  7 
Rash generalised  6 
Skin exfoliation 6 
Angioedema 4 
Blister  4 
Eczema  4 
Photosensitivity reaction  4 
Rash erythematous  4 
Skin burning sensation  4 
Madarosis  3 
Petechiae  3 
Rash macular  3 
Rash maculo-papular  3 
Skin discolouration  3 
Dermatitis contact  2 
Dry skin  2 
129 
 
Mechanical urticaria  2 
Onychoclasis  2 
Scab  2 
Seborrhoea  2 
Skin reaction  2 
Skin tightness  2 
Stevens-Johnson syndrome  2 
Sweat gland disorder  2 
Acne cystic  1 
Dilated pores  1 
Drug eruption  1 
Hair colour changes  1 
Hair disorder  1 
Hair texture abnormal  1 
Nail discolouration  1 
Nail disorder  1 
Onychomadesis  1 
Pigmentation disorder  1 
Piloerection  1 
Rash papular  1 
Sebaceous glands overactivity  1 
Skin depigmentation  1 
Skin disorder  1 
Skin odour abnormal  1 
Skin texture abnormal  1 
Skin ulcer  1 
Skin warm  1 
Telangiectasia  1 
Trichorrhexis  1 
Number of previously unreported ADR’s – 679 
Most common unreported ADR’s- Pruritus, Alopecia and Rash 
Social circumstances Number of incidences reported (46) 
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Loss of personal independence in daily activities  11 
Impaired driving ability  8 
Impaired work ability  8 
Alcohol use  2 
Economic problem  2 
Homicide  2 
Child abuse  1 
Disability  1 
Drug abuser  1 
Impaired quality of life  1 
Imprisonment  1 
Job dissatisfaction  1 
Legal problem  1 
Loss of employment  1 
Marital problem  1 
Physical assault  1 
Refusal of treatment by patient  1 
Theft  1 
Unemployment  1 
Walking aid user  1 
Walking disability  1 
Number of previously unreported ADR’s – 46 
Surgical and medical procedures Number of incidences reported (21) 
Therapy cessation  5 
Surgery  4 
Therapy change  3 
Brain operation  2 
Gastric bypass  1 
Hospitalisation  1 
Knee arthroplasty 1 
Knee operation  1 
Spinal operation  1 
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Steroid therapy  1 
Vasodilation procedure  1 
Number of previously unreported ADR’s – 21 
Vascular disorders Number of incidences reported (93) 
Hypertension  26 
Hot flush  18 
Flushing  15 
Hypotension  12 
Haemorrhage  6 
Shock  4 
Thrombosis  3 
Deep vein thrombosis  2 
Hypertensive crisis  2 
Peripheral coldness  2 
Angiopathy  1 
Arterial occlusive disease  1 
Blood pressure fluctuation  1 
Circulatory collapse  1 
Iliac artery rupture  1 
Pallor  1 
Phlebitis  1 
Shock symptom  1 
Varicose vein  1 
Number of previously unreported ADR’s – 93 
Most common unreported ADR’s- Hypertension  
 
Total number previously unreported ADR’s - 6054 
KEY: 
#- Adverse drug reaction listed in the FDA only 
*- Adverse drug reaction listed in the PIL only 
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APPENDIX: 2 
Search Record Tool  
 
ELECTRONIC SEARCH RECORD 
DATE KEYWORD SEARCHED SEARCH ENGINE USED NO OF 
PUBLICATIONS 
RETRIEVED 
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APPENDIX 3 
 
The PICOS framework will be used for the determination of eligible studies for the primary 
research question. 
 
P - Participant/ Population:   Adolescents aged >12 and adults aged >18 years 
who reported psychiatric adverse effects with the use 
of Vilazodone 
I – Intervention(s), exposure(s):   Vilazodone irrespective of dose and duration 
 C- Comparator(s)/Control: There may be studies comparing psychiatric adverse 
effects and outcomes with vilazodone and other 
antidepressants 
O- Outcome(s):  Psychiatric adverse effects caused with the use of 
vilazodone 
S – Study design: Randomized and controlled trials (RCTs), 
prospective and retrospective cohort studies, cross-
sectional, case series, case reports of vilazodone, and 
comparisons of psychiatric side effects of vilazodone 
with other antidepressants and its effect on mental 
health. 
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APPENDIX: 4 
Search strategy 
 
ELECTRONIC SEARCH RECORD 
 
Date 
 
Keyword searched 
 
Search engine 
used 
Number of 
publications 
received 
 
26/03/20 
[ (Vilazodone OR Viibryd) 
AND 
(5HT1A partial agonists OR antidepressants 
or SSRIs) 
AND 
(Depression, psychiatric disturbances, 
mental disorders, anxiety, depression, 
crying, sleep paralysis, and confusion) 
 
Pubmed 
(Medline) 
 
41 
 
27/03/20 
[ (Vilazodone OR Viibryd) 
AND 
(5HT1A partial agonists OR antidepressants 
or SSRIs) 
AND 
(Depression, psychiatric disturbances, 
mental disorders, anxiety, depression, 
crying, sleep paralysis, and confusion) 
 
Wiley Online 
Library 
 
35 
 
27/03/20 
[ (Vilazodone OR Viibryd) 
AND 
(5HT1A partial agonists OR antidepressants 
or SSRIs) 
AND 
(Depression, psychiatric disturbances, 
mental disorders, anxiety, depression, 
crying, sleep paralysis, and confusion) 
 
Taylor and 
Francis Online 
 
21 
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27/03/20 
[ (Vilazodone OR Viibryd) 
AND 
(5HT1A partial agonists OR antidepressants 
or SSRIs) 
AND 
(Depression, psychiatric disturbances, 
mental disorders, anxiety, depression, 
crying, sleep paralysis, and confusion) 
 
Pysch Info 
 
5 
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APPENDIX: 5 
 
Psychiatric adverse effects listed according to preferred terms in the Medical Dictionary for 
Regulatory Activities (MedDRA) (Le Noury, et al., 2015). 
 
Psychiatric adverse effect Description 
Abnormal dreams vivid, unusual, unpleasant, strange, or bad dreams; 
nightmares or night terrors 
Aggression increased anger 
Anger or easily angered rage, violence, bad temper, hostile, aggressive 
Aggravated depression and 
crying 
new, worsened, or deepened depression, sadness, crying 
spells, uncontrollable crying or tearfulness 
Agitation  irritable, tense, agitated, on edge, little patience or tolerance 
for others 
Akathisia  restlessness, akathisia, can't stop moving, feel like jumping 
out of my skin 
Anxiety new, worsened anxiety, panic attacks 
Low concentration  inability to concentrate or focus, difficulty completing tasks 
Confusion disoriented, fog, brain fog, fuzziness, cloudy, feeling lost or 
confused, disoriented, lacking ability to think or process 
Depersonalization  feeling spacy or dazed, "out of it," "not like myself," stoned 
or drugged, zombie-like, separated from reality, detached 
from my body, unreal disinhibition 
Impulsivity risk-taking, poor judgment, irrational decisions, reduced self-
control, and impulsive, out of character behaviour 
Emotional instability  emotional rollercoaster, feeling "bipolar," moody or mood 
swings, meltdowns, "spazzy," highly unstable emotions 
Emotional numbing  mentally or emotionally numb, unable to feel emotional 
highs or lows, lack of interest in people or activities, 
apathetic, "don't care" attitude, "I feel nothing," emotionally 
dead or flat, socially withdrawn 
Hopelessness feeling of hopelessness, despair, worthlessness, impending 
doom 
Mania hypomania, increased energy, talkative, hyper, feeling 
overcaffeinated or on cocaine, euphoric 
Nervousness  nervous, jittery, jumpy, paranoia, feeling paranoid or having 
strange thoughts 
Psychosis auditory or visual hallucinations, strange (delusional) 
thinking, psychotic 
Sleep paralysis  sleep paralysis, feeling held down or unable to move while 
sleeping 
Suicidal ideation or attempt  new or increased thoughts of suicide or self-harm, suicide 
attempt 
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APPENDIX: 6 
Table 6A- Summary of Risk Bias for Cross-sectional studies examining impact of 
psychiatric adverse effects associated with the use of vilazodone 
 
 
 
 
 
JBI Critical Appraisal checklist for analytical cross-sectional studies 
 Hughes et al 
1. Were the criteria for inclusion in the sample clearly defined?  
2. Were the study subjects and the setting described in detail?  
3. Was the exposure measured in a valid and reliable way?  
4. Were objective, standard criteria used for measurement of the 
condition? 
 
5. Were confounding factors identified?  
6. Were strategies to deal with confounding factors stated?  
7. Were the outcomes measured in a valid and reliable way?  
8. Was appropriate statistical analysis used?   
Comments 100% 
 
KEY:           High Risk 
       Low Risk 
                    Unclear Risk ? 
- 
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Table 6B- Summary of Risk Bias for Cohort studies examining impact of psychiatric 
adverse effects associated with the use of Vilazodone 
 
JBI Critical Appraisal Checklist for Cohort Studies 
 Robinson et al 
1. Were the two groups similar and recruited from the same population?  
2. Were the exposures measured similarly to assign people to both 
exposed and unexposed groups? 
 
3. Was the exposure measured in a valid and reliable way?  
4. Were confounding factors identified?  
5. Were strategies to deal with confounding factors stated?  
6. Were the groups/participants free of the outcome at the start of the 
study (or at the moment of exposure)? 
 
7. Were the outcomes measured in a valid and reliable way?  
8. Was the follow up time reported and sufficient to be long enough for 
outcomes to occur? 
 
9. Was follow up complete, and if not, were the reasons to loss to follow 
up described and explored? 
 
10. Were strategies to address incomplete follow up utilized?  
11. Was appropriate statistical analysis used?  
Comment 73% 
 
KEY:           High Risk 
       Low Risk 
                    Unclear Risk 
 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
? 
- 
? 
? 
? 
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Table 6C- Summary of Risk Bias for Cohort studies (Randomized controlled trials) 
examining the impact of psychiatric adverse effects associated with the use of vilazodone 
 
 
 
 
KEY:           High Risk 
       Low Risk 
                    Unclear Risk 
JBI Critical Appraisal checklist for Randomized Controlled Trials 
 Croft Durgam Gommoll Khan Mathews 
1. Was true randomization used for 
assignment of participants to treatment 
groups? 
     
2. Was allocation to treatment groups 
concealed? 
     
3. Were treatment groups similar at the 
baseline? 
     
4. Were participants blind to treatment 
assignment? 
     
5. Were those delivering treatment blind 
to treatment assignment? 
     
6. Were outcomes assessors blind to 
treatment assignment? 
  
 
   
7. Were treatment groups treated 
identically other than the intervention of 
interest? 
     
8. Was follow up complete and if not, 
were differences between groups in 
terms of their follow up adequately 
described and analysed? 
     
9. Were participants analysed in the 
groups to which they were randomized? 
     
10. Were outcomes measured in the 
same way for treatment groups 
     
11. Were outcomes measured in a 
reliable way? 
     
12. Was appropriate statistical analysis 
used? 
     
13. Was the trial design appropriate, 
and any deviations  
from the standard RCT design 
(individual randomization, parallel 
groups) accounted for in the conduct 
and analysis of the trial 
     
 92% 85% 85% 85% 92% 
? 
- 
+ 
? ? ? ? ? 
? ? ? 
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Appendix: 7- PRISMA checklist 
 
                                                                                                 
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or 
both.  
47 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: 
background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis 
methods; results; limitations; conclusions and implications of key 
findings; systematic review registration number.  
48 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is 
already known.  
49 
Objectives  4 Provide an explicit statement of questions being addressed with 
reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS).  
49 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be 
accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
50 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) 
and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
51 
Information 
sources  
7 Describe all information sources (e.g., databases with dates of 
coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
50 
Search  8 Present full electronic search strategy for at least one database, 
including any limits used, such that it could be repeated.  
50 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, 
included in systematic review, and, if applicable, included in the 
meta-analysis).  
51 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted 
forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
51 and 52 
Data items  11 List and define all variables for which data were sought (e.g., 
PICOS, funding sources) and any assumptions and 
simplifications made.  
51 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual 
studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used 
in any data synthesis.  
51 and 52 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, difference 
in means).  
- 
Synthesis of 
results  
14 Describe the methods of handling data and combining results of 
studies, if done, including measures of consistency (e.g., I2) for 
each meta-analysis.  
52 
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Section/topic  # Checklist item  
Reported on 
page #  
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the 
cumulative evidence (e.g., publication bias, selective reporting 
within studies).  
51 and 52 
Additional 
analyses  
16 Describe methods of additional analyses (e.g., sensitivity or 
subgroup analyses, meta-regression), if done, indicating which 
were pre-specified.  
- 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and 
included in the review, with reasons for exclusions at each 
stage, ideally with a flow diagram.  
53 
Study 
characteristics  
18 For each study, present characteristics for which data were 
extracted (e.g., study size, PICOS, follow-up period) and provide 
the citations.  
54 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any 
outcome level assessment (see item 12).  
54 
Results of 
individual studies  
20 For all outcomes considered (benefits or harms), present, for 
each study: (a) simple summary data for each intervention group 
(b) effect estimates and confidence intervals, ideally with a forest 
plot.  
55-60 
Synthesis of 
results  
21 Present results of each meta-analysis done, including 
confidence intervals and measures of consistency.  
61-62 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across studies 
(see Item 15).  
Appendix: 6 
137-139 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or 
subgroup analyses, meta-regression [see Item 16]).  
- 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence 
for each main outcome; consider their relevance to key groups 
(e.g., healthcare providers, users, and policy makers).  
64-67 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), 
and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias).  
67 
Conclusions  26 Provide a general interpretation of the results in the context of 
other evidence, and implications for future research.  
67-68 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other 
support (e.g., supply of data); role of funders for the systematic 
review.  
68 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
 
 
 
